

CITATION REPORT

List of articles citing

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

DOI: 10.1001/2013.jamapsychiatry.4
JAMA Psychiatry, 2013, 70, 31-41.

Source: <https://exaly.com/paper-pdf/56102676/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1197	Next-generation treatments for mental disorders. 2012 , 4, 155ps19		111
1196	The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?. 2012 , 12, 1339-50		57
1195	Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. 2013 , 30, 297-306		450
1194	Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. 2013 , 31, 1-8		64
1193	Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression. 2013 , 63, 187-94		82
1192	Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. 2013 , 11, 129		406
1191	The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [¹¹ C]PBR28 PET study. 2013 , 33, 131-8		155
1190	The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation. 2013 , 33, 1855-64		19
1189	The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. 2013 , 19, 87-101		23
1188	Inflammation and schizophrenia. 2013 , 39, 1174-9		207
1187	Evidence Linking Mental Health with Obesity and Metabolic Syndrome: The Role of Inflammation. 2013 , 2, 181-188		
1186	Neuroinflammation in Mood Disorders. 2013 , 317-331		1
1185	Overenthousiast immuunsysteem pakt ongelukkig uit. 2013 , 17, 161-166		
1184	The role of the innate immune system in psychiatric disorders. 2013 , 53, 52-62		193
1183	Is anxious-depression an inflammatory state?. 2013 , 81, 577-81		31
1182	Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment. 2013 , 33, 183-9		166
1181	The vascular depression hypothesis: mechanisms linking vascular disease with depression. 2013 , 18, 963-74		517

1180	Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. 2013 , 45, 92-9	142
1179	Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. 2013 , 246, 199-229	601
1178	Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. 2013 , 11, 74	129
1177	Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. 2013 , 73, 1133-41	302
1176	Evidence for a dysregulated immune system in the etiology of psychiatric disorders. 2013 , 8, 900-20	123
1175	Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. 2013 , 31, 205-15	51
1174	The neurobiological correlates of childhood adversity and implications for treatment. 2013 , 128, 434-47	100
1173	Psychopharmacologic Treatment of Depression in Patients With Cancer: A 2013 Update. 2013 , 11, 450-459	2
1172	Childhood microbial experience, immunoregulation, inflammation and adult susceptibility to psychosocial stressors and depression in rich and poor countries. 2013 , 2013, 14-7	28
1171	Microbial 'Old Friends', immunoregulation and stress resilience. 2013 , 2013, 46-64	128
1170	Infliximab and its rapidly emerging role in the management of psychiatric disorders. 2013 , 47, 964-5	
1169	A case of anorexia nervosa with comorbid Crohn's disease: beneficial effects of anti-TNF- α therapy?. 2013 , 46, 639-41	26
1168	Psychoneuroimmunoendocrinology: the biological basis of mind-body physiology and pathophysiology. 2013 , 30, 285-7	9
1167	DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. 2013 , 3, e300	55
1166	The association between immune activation and manic symptoms in patients with a depressive disorder. 2013 , 3, e314	47
1165	Peripheral elevation of TNF- α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis. 2013 , 110, 10306-11	62
1164	Quest for biomarkers of treatment-resistant depression: shifting the paradigm toward risk. <i>Frontiers in Psychiatry</i> , 2013 , 4, 57	5 10
1163	Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability. 2013 , 8, e60435	32

1162	Mind and body: how the health of the body impacts on neuropsychiatry. 2013 , 4, 158		32
1161	Treating depression and depression-like behavior with physical activity: an immune perspective. <i>Frontiers in Psychiatry</i> , 2013 , 4, 3	5	81
1160	Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). 2014 , 75, e1428-32		99
1159	Immune modulation of the brain-gut-microbe axis. 2014 , 5, 146		91
1158	Kynurenines in CNS disease: regulation by inflammatory cytokines. 2014 , 8, 12		215
1157	. 2014 ,		2
1156	Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. 2014 , 17, 1599-608		75
1155	Inflammatory activation is associated with a reduced glucocorticoid receptor alpha/beta expression ratio in monocytes of inpatients with melancholic major depressive disorder. 2014 , 4, e344		87
1154	Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders. 2014 , 21, 140-4		13
1153	Putting evidence into practice: evidence-based interventions for depression. 2014 , 18 Suppl, 26-37		12
1152	From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. 2014 , 140, 774-815		1015
1151	Infectious Diseases and Mental Health. 2014 , 99-113		7
1150	Cardiac autonomic imbalance by social stress in rodents: understanding putative biomarkers. 2014 , 5, 950		17
1149	An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. 2014 , 171, 1278-86		267
1148	The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. 2014 , 39, 802-10		78
1147	Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. 2014 , 130, 163-80		83
1146	Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection. 2014 , 4, 123-42		32
1145	Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. 2014 , 129, 163-79		127

1144	Depression and IBD. 2014 , 58, 543-4		3
1143	Calretinin and pathologic diagnosis of Hirschsprung disease: has the time come to abandon the acetylcholinesterase stain?. 2014 , 58, 544-5		5
1142	Infantile hypertrophic pyloric stenosis: closing in on the cause. 2014 , 58, 545		
1141	Inflammation and depression: unraveling the complex interplay in inflammatory bowel disease. 2014 , 58, 541-2		6
1140	Depression subtypes in pediatric inflammatory bowel disease. 2014 , 58, 574-81		39
1139	Inflammation in the Pathogenesis of Depression. 2014 , 261-288		1
1138	Depressive symptoms and immune response to meningococcal conjugate vaccine in early adolescence. 2014 , 26, 1567-76		13
1137	The integrative management of treatment-resistant depression: a comprehensive review and perspectives. 2014 , 83, 70-88		75
1136	The association between depressive symptoms, cognitive function, and inflammation in major depression. 2014 , 35, 70-6		109
1135	Cytokine gene variations associated with subsyndromal depressive symptoms in patients with breast cancer. 2014 , 18, 397-404		16
1134	Race differences in the relation of vitamins A, C, E, and β -carotene to metabolic and inflammatory biomarkers. 2014 , 34, 1-10		16
1133	Dietary restriction reverses obesity-induced anhedonia. 2014 , 128, 126-32		21
1132	Further evidence for plasma progranulin as a biomarker in bipolar disorder. <i>Journal of Affective Disorders</i> , 2014 , 157, 87-91	6.6	22
1131	Inflammation: its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics. 2014 , 231, 317-8		32
1130	Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. <i>Journal of Affective Disorders</i> , 2014 , 156, 1-7	6.6	242
1129	Targeting the inflammatory pathway as a therapeutic tool for major depression. 2014 , 21, 131-9		34
1128	Annual research review: The neuroinflammation hypothesis for stress and psychopathology in children--developmental psychoneuroimmunology. 2014 , 55, 615-31		42
1127	Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression?. 2014 , 121, 925-32		89

1126	The biology of depression in cancer and the relationship between depression and cancer progression. 2014 , 26, 16-30	92
1125	Depression as a risk factor for cancer: from pathophysiological advances to treatment implications. 2014 , 65, 203-21	64
1124	The cytokine model of schizophrenia: emerging therapeutic strategies. 2014 , 75, 292-299	83
1123	Inflamed moods: a review of the interactions between inflammation and mood disorders. 2014 , 53, 23-34	363
1122	A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. 2014 , 48, 102-11	234
1121	Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. 2014 , 19, 699-709	401
1120	Heartsick: psychiatric and inflammatory implications of cerebrovascular disease. 2014 , 29, 577-85	2
1119	Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?. 2014 , 15, 2-16	20
1118	The neuro-immune axis: prospect for novel treatments for mental disorders. 2014 , 114, 128-36	21
1117	Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. 2014 , 39, 1624-34	80
1116	Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach. 2014 , 28, 570-81	11
1115	Neurotherapeutic implications of brain-immune interactions. 2014 , 39, 242-3	9
1114	The effects of inflammation, infection and antibiotics on the microbiota-gut-brain axis. 2014 , 817, 279-89	57
1113	Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. 2014 , 111, 16136-41	424
1112	Microbiota, immunoregulatory old friends and psychiatric disorders. 2014 , 817, 319-56	74
1111	Emerging antidepressants to treat major depressive disorder. 2014 , 12, 7-16	29
1110	Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation. 2014 , 54, 289-98	25
1109	A review of the relationship between proinflammatory cytokines and major depressive disorder. <i>Journal of Affective Disorders</i> , 2014 , 169, 15-20	6.6 262

1108	Cancer-related fatigue--mechanisms, risk factors, and treatments. 2014 , 11, 597-609	629
1107	Exploratory associations with tumor necrosis factor- β disinhibition and suicidal endorsement after traumatic brain injury. 2014 , 41, 134-43	54
1106	Neuroimmunomodulation in depression: a review of inflammatory cytokines involved in this process. 2014 , 39, 1634-9	21
1105	Perfusion deficits, inflammation and aging precipitate depressive behaviour. 2014 , 15, 439-48	49
1104	Depression in silent lacunar infarction: a cross-sectional study of its association with location of silent lacunar infarction and vascular risk factors. 2014 , 35, 1553-9	19
1103	Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. 2014 , 53, 274-96	164
1102	Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease. 2014 ,	40
1101	Pharma-Nutrition. 2014 ,	
1100	Vagus Nerve Stimulation. 2014 , 1, 64-73	179
1099	Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. 2014 , 48, 79-85	117
1098	Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. 2014 , 36, 71-9	61
1097	Neuropsychological features of adult mastocytosis. 2014 , 34, 407-22	30
1096	Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. 2014 , 76, 559-66	143
1095	Pretreatment brain states identify likely nonresponse to standard treatments for depression. 2014 , 76, 527-35	99
1094	Atopic disorders and depression: findings from a large, population-based study. <i>Journal of Affective Disorders</i> , 2014 , 155, 261-5	6.6 59
1093	Microbial 'old friends', immunoregulation and socioeconomic status. 2014 , 177, 1-12	135
1092	Immunology of major depression. 2014 , 21, 123-30	110
1091	The 2014 National Nursing Research Roundtable: The science of caregiving. 2014 , 62, 362-5	7

1090	New Developments With Vagus Nerve Stimulation Therapy. 2014 , 52, 11-14	13
1089	Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro [®] 1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. 2014 , 4, 349-60	50
1088	Nutrition, psychoneuroimmunology and depression: the therapeutic implications of omega-3 fatty acids in interferon- γ -induced depression. 2015 , 5, 21	23
1087	Neuroendocrine and viral correlates of premature immunosenescence. 2015 , 1351, 11-21	26
1086	Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study. 2015 , 173, 471-9	14
1085	Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease. 2015 , 21, 1047-53	12
1084	Perineal Injury During Childbirth Increases Risk of Postpartum Depressive Symptoms and Inflammatory Markers. 2015 , 60, 428-36	21
1083	The Involvement of TNF- α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. 2015 , 13, 558-76	80
1082	Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers. 2015 , 9, 18	17
1081	Research domain criteria: a final paradigm for psychiatry?. 2015 , 9, 488	4
1080	Nuevos enfoques para tratar la depresi ^o n resistente [translation of New approaches to treating resistant depression] by Rodolfo Zaratiegui]. 2015 , 21,	
1079	Hepatocyte nuclear factor 4 alpha is a key factor related to depression and physiological homeostasis in the mouse brain. 2015 , 10, e0119021	25
1078	Somatic influences on subjective well-being and affective disorders: the convergence of thermosensory and central serotonergic systems. 2014 , 5, 1580	30
1077	Depression and frailty in later life: a systematic review. 2015 , 10, 1947-58	174
1076	Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics. 2015 , 13, 616-35	30
1075	Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson's Disease. 2015 , 2015, 108179	12
1074	Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease. 2015 , 21, 1321-8	28
1073	Peripheral Administration of Tumor Necrosis Factor-Alpha Induces Neuroinflammation and Sickness but Not Depressive-Like Behavior in Mice. 2015 , 2015, 716920	42

1072	Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. 2015 , 13, 636-55	40
1071	The Role of the Microbiome in Mental Health: A Psychoneuroimmunologic Perspective. 2015 , 21, 61-67	1
1070	Inflammatory Factors Mediate Vulnerability to a Social Stress-Induced Depressive-like Phenotype in Passive Coping Rats. 2015 , 78, 38-48	94
1069	Risk and Resilience: Animal Models Shed Light on the Pivotal Role of Inflammation in Individual Differences in Stress-Induced Depression. 2015 , 78, 7-9	17
1068	Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. 2015 , 95, 81-97	145
1067	Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. 2015 , 2, 258-270	423
1066	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. 2015 , 29, 459-525	381
1065	Increased CRP levels may be a trait marker of suicidal attempt. 2015 , 25, 1824-31	47
1064	Levodopa reverses cytokine-induced reductions in striatal dopamine release. 2015 , 18,	41
1063	Psychosocial Support of the Inflammatory Bowel Disease Patient. 2015 , 95, 1281-93, vii-viii	7
1062	Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. 2015 , 5, e689	47
1061	Chronic inflammation: a new therapeutic target for post-traumatic stress disorder?. 2015 , 2, 954-5	16
1060	IL-23 and TGF- β levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. <i>Journal of Affective Disorders</i> , 2015 , 174, 361-6	6.6 40
1059	Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. 2015 , 52, 89-104	185
1058	Novel investigational drugs targeting IL-6 signaling for the treatment of depression. 2015 , 24, 459-75	35
1057	Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. 2015 , 72, 86-96	119
1056	Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. 2015 , 29, 1063-70	59
1055	Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. 2015 , 60, 465-70	42

1054	Sick and tired: mood, fatigue, and inflammation in cancer. 2015 , 17, 555		8
1053	Cognitive dysfunction in depression - pathophysiology and novel targets. 2014 , 13, 1819-35		66
1052	Quantitative Magnetization Transfer Imaging as a Biomarker for Effects of Systemic Inflammation on the Brain. 2015 , 78, 49-57		78
1051	Cytokine gene associations with self-report ratings of morning and evening fatigue in oncology patients and their family caregivers. 2015 , 17, 175-84		33
1050	Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. 2015 , 293, 198-202		40
1049	Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial. <i>Journal of Affective Disorders</i> , 2015 , 185, 209-13	6.6	19
1048	Early identification of treatment non-response utilizing the Patient Health Questionnaire (PHQ-9). 2015 , 68, 114-9		12
1047	Tumour necrosis factor- α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety. 2015 , 79, 175-84		72
1046	Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. 2015 , 20, 1142-50		80
1045	Inflammation and clinical response to treatment in depression: A meta-analysis. 2015 , 25, 1532-43		360
1044	Examining the role of neuroinflammation in major depression. 2015 , 229, 27-36		123
1043	Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis. 2015 , 41, 1162-70		166
1042	A systematic review of randomised control trials on the effects of yoga on stress measures and mood. 2015 , 68, 270-82		145
1041	Major Depression: An Immune-Inflammatory Disorder. 2015 , 147-159		1
1040	Depression. 2015 , 1253-1274		1
1039	Inflammation in schizophrenia: A question of balance. 2015 , 55, 612-26		122
1038	State of the Art Review: Depression, Stress, Anxiety, and Cardiovascular Disease. 2015 , 28, 1295-302		396
1037	Unhealthy lifestyle may increase later depression via inflammation in older women but not men. 2015 , 63, 65-74		21

1036	Immunomodulatory activity of ketamine in human astroglial A172 cells: Possible relevance to its rapid antidepressant activity. 2015 , 282, 33-8		11
1035	Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of trauma. 2015 , 172, 353-62		129
1034	C-reactive protein: A stress diathesis marker at the crossroads of maladaptive behavioral and cardiometabolic sequelae. 2015 , 172, 307-9		12
1033	Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies. 2015 , 19, 927-39		18
1032	Immune abnormalities across psychiatric disorders: clinical relevance. 2015 , 21, 150-156		4
1031	Are Anti-inflammatory Therapies Viable Treatments for Psychiatric Disorders?: Where the Rubber Meets the Road. <i>JAMA Psychiatry</i> , 2015 , 72, 527-8	14.5	71
1030	Immunology and Psychiatry. 2015 ,		3
1029	Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. 2015 , 132, 180-91		62
1028	The hippocampus and TNF: Common links between chronic pain and depression. 2015 , 53, 139-59		114
1027	Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder. 2015 , 20, 562-8		9
1026	Neuroimmune mechanisms of depression. 2015 , 18, 1386-93		312
1025	New approaches to treating resistant depression. 2015 , 21, 315-323		9
1024	Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. 2015 , 139, 481-6		34
1023	Depression as a microglial disease. 2015 , 38, 637-658		423
1022	Translating depression biomarkers for improved targeted therapies. 2015 , 59, 1-15		17
1021	The Neurobiology of Motivational Deficits in Depression--An Update on Candidate Pathomechanisms. 2016 , 27, 337-55		32
1020	Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression. 2015 , 287, 88-92		38
1019	Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. 2015 , 229, 37-48		117

1018	Five potential therapeutic agents as antidepressants: a brief review and future directions. 2015 , 15, 1015-29		7
1017	Acute coronary syndrome and depression: A review of shared pathophysiological pathways. 2015 , 49, 994-1005		11
1016	Neurological disorders, depression and inflammation: is there a common link?. 2015 , 10, 327-343		5
1015	IL-8 and the innate immunity as biomarkers in acute child and adolescent psychopathology. 2015 , 62, 233-42		24
1014	Inflammation: depression fans the flames and feasts on the heat. 2015 , 172, 1075-91		383
1013	Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. <i>Journal of Affective Disorders</i> , 2015 , 188, 149-59	6.6	94
1012	Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein. 2015 , 3, 449-460		17
1011	Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. 2015 , 132, 965-86		264
1010	Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. <i>Journal of Affective Disorders</i> , 2015 , 174, 467-78	6.6	40
1009	Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. 2015 , 47, 193-200		47
1008	Astrocytic TNF α regulates the behavioral response to antidepressants. 2015 , 44, 187-94		12
1007	Altered inflammatory activity associated with reduced hippocampal volume and more severe posttraumatic stress symptoms in Gulf War veterans. 2015 , 51, 557-66		56
1006	Integrating the monoamine, neurotrophin and cytokine hypotheses of depression--a central role for the serotonin transporter?. 2015 , 147, 1-11		99
1005	Why sleep is important for health: a psychoneuroimmunology perspective. 2015 , 66, 143-72		507
1004	Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies. 2015 , 51, 237-52		127
1003	A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. 2015 , 57, 11-6		69
1002	Clinical characteristics of inflammation-associated depression: Monocyte gene expression is age-related in major depressive disorder. 2015 , 44, 48-56		51
1001	Adult neurogenesis and mental illness. 2015 , 40, 113-28		106

1000	Faster, better, stronger: towards new antidepressant therapeutic strategies. 2015 , 753, 32-50	65
999	Role of Inflammation in Psychiatric Disease. 2015 , 396-421	2
998	Inflammatory cytokine-associated depression. 2015 , 1617, 113-25	92
997	Emotion Dysregulation and Inflammation in African-American Women with Type 2 Diabetes. 2016 , 2016, 8926840	17
996	IL-6 and IL-10 levels in the umbilical cord blood of newborns with a history of crack/cocaine exposure in utero: a comparative study. 2016 , 38, 40-9	4
995	Staging Models in Bipolar Disorder: A Systematic Review of the Literature. 2016 , 14, 117-30	52
994	Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. 2016 , 14, 732-42	232
993	Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. 2016 , 2016, 3476240	24
992	The HPA Axis in the Pathogenesis and Treatment of Depressive Disorders: Integrating Clinical and Molecular Findings. 2016 , a3, 64-76	9
991	The Neurobiology of Bipolar Disorder: An Integrated Approach. 2016 , 52, 18-37	43
990	Neuroimmune Interface in the Comorbidity between Alcohol Use Disorder and Major Depression. 2016 , 7, 655	39
989	Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor- α (TNF- α) in Major Depressive Disorder: A Systematic Review. 2016 , 17,	85
988	Inflammation and cognition in major depressive disorder. 160-178	
987	The Neuroinflammation Perspective of Depression: Reuniting the Outstanding Mechanisms of the Pathophysiology. 2016 , 26, 196-206	9
986	Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2016 , 7, 72	5 38
985	The Comorbidity of Bipolar Disorder and Migraine: The Role of Inflammation and Oxidative and Nitrosative Stress. 2016 , 16, 179-86	7
984	Neuroendocrine and Neurochemical Processes in Depression. 2016 , a3, 3-15	5
983	Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. 2016 , 78, 26-37	35

982	Molecular serum signature of treatment resistant depression. 2016 , 233, 3051-9	13
981	Pharmacologic implications of inflammatory comorbidity in bipolar disorder. 2016 , 29, 63-9	16
980	Depression Phenotype, Inflammation, and the Brain: Implications for Future Research. 2016 , 78, 384-8	15
979	Glial biomarkers in human central nervous system disease. 2016 , 64, 1755-71	31
978	PDE4B as a microglia target to reduce neuroinflammation. 2016 , 64, 1698-709	41
977	Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid β and TNF α Mediated Synaptic Plasticity Disruption in the Rat Hippocampus. 2017 , 27, 3724-3735	13
976	C-reactive protein in bipolar disorder. 2016 , 3, 1096-1098	3
975	Does CRP predict outcome in bipolar disorder in regular outpatient care?. 2016 , 4, 14	8
974	Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. 2016 , 70, 117-26	36
973	Neuroinflammation at the interface of depression and cardiovascular disease: Evidence from rodent models of social stress. 2016 , 4, 1-14	40
972	Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders. 2017 , 31, 249-267	39
971	Depression in Autoimmune Diseases. 2017 , 31, 139-154	31
970	The Role of Dopamine in Inflammation-Associated Depression: Mechanisms and Therapeutic Implications. 2017 , 31, 199-219	48
969	Low-grade inflammation is a major contributor of impaired attentional set shifting in obese subjects. 2016 , 58, 63-68	30
968	Hippocampal Neuroinflammation and Depression: Relevance to Multiple Sclerosis and Other Neuropsychiatric Illnesses. 2016 , 80, e1-2	4
967	Association between C-reactive protein and suicidal behavior in an adult inpatient population. 2016 , 79, 28-33	27
966	Neuroscience, mental health and the immune system: overcoming the brain-mind-body trichotomy. 2016 , 25, 101-5	24
965	Evidence for Inflammation-Associated Depression. 2017 , 31, 3-30	51

964	What's Hot in Schizophrenia Research?. 2016 , 39, 343-51	10
963	Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. 2016 , 22, 238-49	732
962	Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages. 2016 , 241, 1540-50	17
961	Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. 2016 , 56, 281-8	75
960	Are the emergence of affective disturbances in neuropathic pain states contingent on supraspinal neuroinflammation?. 2016 , 56, 397-411	48
959	The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets. 2016 , 50, 618-30	21
958	Chronic subordinate colony housing paradigm: A mouse model for mechanisms of PTSD vulnerability, targeted prevention, and treatment-2016 Curt Richter Award Paper. 2016 , 74, 221-230	40
957	Immune-to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression. 2017 , 31, 73-94	97
956	Role of Neuro-Immunological Factors in the Pathophysiology of Mood Disorders: Implications for Novel Therapeutics for Treatment Resistant Depression. 2017 , 31, 339-356	33
955	Commentary on the 2016 named series: Neuroimaging, inflammation and behavior. 2016 , 58, 48-51	2
954	Low-dose lipopolysaccharide (LPS) inhibits aggressive and augments depressive behaviours in a chronic mild stress model in mice. <i>Journal of Neuroinflammation</i> , 2016 , 13, 108	10.1 60
953	Opposite in vivo effects of agents that stimulate or inhibit the glutamate/cysteine exchanger system xc ⁻ on the inhibition of hippocampal LTP by A β . 2016 , 26, 1655-1665	3
952	Mental disorders in HIV/HCV coinfecting patients under antiviral treatment for hepatitis C. 2016 , 246, 173-181	7
951	Major depressive disorder. 2016 , 2, 16065	635
950	New translational perspectives for blood-based biomarkers of PTSD: From glucocorticoid to immune mediators of stress susceptibility. 2016 , 284, 133-140	56
949	Metabolic-Inflammation Aspects of Depression and Cardiovascular Disease. 2016 , 211-233	
948	Anti-inflammatory Agents for the Treatment of Depression in the Light of Comorbid Cardiovascular Disease. 2016 , 445-465	
947	Differential effects of peripheral and brain tumor necrosis factor on inflammation, sickness, emotional behavior and memory in mice. 2016 , 58, 310-326	27

946	Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. 2016 , 21, 184-98		112
945	Psychological side effects of immune therapies: symptoms and pathomechanism. 2016 , 29, 97-103		19
944	The Depressed Frail Phenotype: The Clinical Manifestation of Increased Biological Aging. 2016 , 24, 1084-1094	57	
943	Clinical Perspectives on Targeting Therapies for Personalized Medicine. 2016 , 102, 79-114		5
942	The Microbiota, Immunoregulation, and Mental Health: Implications for Public Health. 2016 , 3, 270-86		126
941	Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy. <i>Journal of Affective Disorders</i> , 2016 , 205, 60-68	6.6	39
940	Interleukin-1 β -targeted treatment strategies in inflammatory depression: toward personalized care. 2016 , 134, 469-484		27
939	Neuropathology of mood disorders: do we see the stigmata of inflammation?. 2016 , 6, e946		89
938	The significance of routine biochemical markers in patients with major depressive disorder. <i>Scientific Reports</i> , 2016 , 6, 34402	4.9	22
937	Physical health and metabolic dysfunction in bipolar disorder. 256-268		
936	Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders. 2016 , 17, 47		6
935	Psychiatry outpatient visits by atopic dermatitis patients varying in the complexity of their prescriptions: A nationwide cohort study conducted from 2005 to 2013. 2016 , 95, e5411		5
934	Integrating neuroimmune systems in the neurobiology of depression. 2016 , 17, 497-511		338
933	Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1 β mRNA Levels Accurately Predict Treatment Response in Depressed Patients. 2016 , 19,		77
932	Inflammation and the Silent Sequelae of Stroke. 2016 , 13, 801-810		23
931	Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. 2016 , 18, 89-101		125
930	Is there a role for immune-to-brain communication in schizophrenia?. 2016 , 233, 1559-73		98
929	Pathogenesis of depression: Insights from human and rodent studies. 2016 , 321, 138-162		238

928	Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. 2016 , 233, 1679-88	53
927	Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. 2016 , 21, 1511-1516	50
926	Role of neuro-immunological factors in the pathophysiology of mood disorders. 2016 , 233, 1623-36	91
925	Amyloid Hypothesis: Is There a Role for Anti-amyloid Treatment in Late-Life Depression?. 2016 , 24, 239-47	38
924	Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. 2016 , 21, 1351-7	157
923	Glucocorticoid mediated regulation of inflammation in human monocytes is associated with depressive mood and obesity. 2016 , 66, 195-204	21
922	Stress-Related Immune Markers in Depression: Implications for Treatment. 2016 , 19,	39
921	Neuroinflammation in Suicide. 2016 , 111-133	1
920	Mastocytosis in adulthood and neuropsychiatric disorders. 2016 , 174, 77-85.e1	26
919	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. 2016 , 64, 148-66	79
918	Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. 2016 ,	2
917	Bipolar Disorder and Inflammation. 2016 , 39, 125-37	83
916	Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor. 2016 , 80, 12-22	211
915	Inflammatory mechanisms contribute to microembolism-induced anxiety-like and depressive-like behaviors. 2016 , 303, 160-7	6
914	The Case for Adjunctive Monoclonal Antibody Immunotherapy in Schizophrenia. 2016 , 39, 187-98	28
913	Evaluation of periodontitis in hospital outpatients with major depressive disorder. A focus on gingival and circulating cytokines. 2016 , 53, 49-53	5
912	Associations of low grade inflammation and endothelial dysfunction with depression - The Maastricht Study. 2016 , 56, 390-6	71
911	Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study. 2016 , 6, e709	22

910	Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. 2016 , 166, 14-21	32
909	The role of inflammation in depression: from evolutionary imperative to modern treatment target. 2016 , 16, 22-34	1623
908	Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. 2016 , 51, 29-38	35
907	Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. 2016 , 21, 1358-65	302
906	Microbiome to Brain: Unravelling the Multidirectional Axes of Communication. 2016 , 874, 301-36	41
905	Microglia activation is associated with IFN- γ -induced depressive-like behavior. 2016 , 55, 105-113	47
904	Candidate Risks Indicators for Bipolar Disorder: Early Intervention Opportunities in High-Risk Youth. 2015 , 19,	38
903	S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression. 2015 , 19, pyv103	28
902	Early-Life Adversity and Physical and Emotional Health Across the Lifespan: A Neuroimmune Network Hypothesis. 2016 , 80, 23-32	322
901	The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. 2016 , 65, 134-44	121
900	Inflammation, Depression, and Slow Gait: A High Mortality Phenotype in Later Life. 2016 , 71, 221-7	44
899	Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor- α . 2016 , 21, 642-9	547
898	Anti-inflammatory strategies in the treatment of schizophrenia. 2016 , 9, 161-3	16
897	The impact of mitochondrial aldehyde dehydrogenase (ALDH2) activation by Alda-1 on the behavioral and biochemical disturbances in animal model of depression. 2016 , 51, 144-153	20
896	Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?. 2016 , 233, 1575-89	112
895	Neuroinflammation in suicide: Toward a comprehensive model. 2016 , 17, 564-586	63
894	Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. 2016 , 21, 71-9	175
893	Low-grade inflammation predicts persistence of depressive symptoms. 2016 , 233, 1669-78	108

892	Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. 2016 , 53, 2927-2935	30
891	Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders. 2017 , 112, 307-323	73
890	Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience. 2017 , 42, 62-80	167
889	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. 2017 , 51, 355-365	17
888	Role of Adiposity-Driven Inflammation in Depressive Morbidity. 2017 , 42, 115-128	88
887	Role of Inflammation in Suicide: From Mechanisms to Treatment. 2017 , 42, 271-283	88
886	Immunological biomarkers associated with brain structure and executive function in late-life depression: exploratory pilot study. 2017 , 32, 692-699	24
885	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. 2017 , 34, 281-290	9
884	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. 2017 , 78, 105-113	118
883	Early onset of inflammation during ontogeny of bipolar disorder: the NLRP2 inflammasome gene distinctly differentiates between patients and healthy controls in the transition between iPS cell and neural stem cell stages. 2017 , 7, e1010	23
882	Microglia in the dorsal raphe nucleus plays a potential role in both suicide facilitation and prevention in affective disorders. 2017 , 267, 403-415	38
881	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. 2017 , 62, 212-218	86
880	Muscle fatigability and depressive symptoms in later life. 2017 , 32, e166-e172	8
879	The link between inflammation, bugs, the intestine and the brain in alcohol dependence. 2017 , 7, e1048	90
878	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. 2017 , 62, 344-350	128
877	Biological profiling of prospective antidepressant response in major depressive disorder: Associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity. 2017 , 79, 84-92	18
876	Genetic and serum biomarker evidence for a relationship between TNF α and PTSD in Vietnam war combat veterans. 2017 , 74, 125-133	23
875	A role for the peripheral immune system in the development of alcohol use disorders?. 2017 , 122, 148-160	51

874	The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis?. 2017 , 3, 3		252
873	Psoriasis, Depression, and Inflammatory Overlap: A Review. 2017 , 18, 613-620		37
872	Immunopsychiatry: important facts. 2017 , 47, 2229-2237		68
871	Dilated Virchow-Robin spaces in the hippocampus impact behaviors and effects of anti-depressant treatment in model of depressed rats. <i>Journal of Affective Disorders</i> , 2017 , 219, 17-24	6.6	9
870	Acute and chronic treatment with quetiapine induces antidepressant-like behavior and exerts antioxidant effects in the rat brain. 2017 , 32, 1195-1208		15
869	Brain microglia in psychiatric disorders. 2017 , 4, 563-572		124
868	Vitamin D supplementation in multiple sclerosis: Symptoms and biomarkers of depression. 2017 , 378, 30-35		29
867	Targeting the Immune System with Pharmacotherapy in Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2017 , 4, 139-151	3.1	7
866	Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder. <i>Journal of Affective Disorders</i> , 2017 , 221, 151-157	6.6	1
865	Immunopathology of the Nervous System. 2017 , 123-219		
864	Beyond serotonin: newer antidepressants in the future. 2017 , 17, 777-790		11
863	Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. 2018 , 55, 4195-4206		200
862	Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. 2017 , 7, e1065		102
861	Do Statins Have Antidepressant Effects?. 2017 , 31, 335-343		16
860	Interleukin-4 is a participant in the regulation of depressive-like behavior. 2017 , 326, 165-172		21
859	Depression with inflammation: longitudinal analysis of a proposed depressive subtype in community dwelling older adults. 2017 , 32, e18-e24		18
858	Mood Disorders and Severe Obesity: A Case Study. 2017 , 107-121		
857	Monoclonal antibody immunotherapy in psychiatric disorders. 2017 , 4, 13-15		13

856	Inflammation-Associated Depression: Evidence, Mechanisms and Implications. 2017,		17
855	Sirukumab: A Potential Treatment for Mood Disorders?. 2017, 34, 78-90		23
854	Psychiatric Care in Severe Obesity. 2017,		1
853	Pharmacological and Nonpharmacological Interventions to Arrest Neuroprogression in Psychiatric Disorders. 2017, 31, 162-176		3
852	Bipolar Disorder and the Vascular System: Mechanisms and New Prevention Opportunities. 2017, 33, 1565-1576		41
851	Dementia Risk in Posttraumatic Stress Disorder: the Relevance of Sleep-Related Abnormalities in Brain Structure, Amyloid, and Inflammation. 2017, 19, 89		16
850	Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. <i>JAMA Psychiatry</i> , 2017, 74, 1214-1225	14.5	109
849	To Boldly Go Where One Has Gone Before. 2017, 66, 1-8		6
848	Backing into the future: pharmacological approaches to the management of resistant depression. 2017, 47, 2569-2577		21
847	Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial. 2017, 31, 1166-1175		77
846	Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. 2017, 31, 1137-1148		70
845	Inflammatory illness: Why the next wave of antidepressants may target the immune system. 2017, 23, 1009-1011		7
844	Correction: Breaking through: How researchers are gaining entry into barricaded bacteria. 2017, 23, 1011		
843	Drug repurposing may generate novel approaches to treating depression. 2017, 69, 1428-1436		18
842	Molecular hydrogen increases resilience to stress in mice. <i>Scientific Reports</i> , 2017, 7, 9625	4.9	24
841	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. 2017, 66, 103-110		47
840	Associations of C-reactive protein and psychological distress are modified by antidepressants, supporting an inflammatory depression subtype: Findings from UKHLS. 2017, 66, 89-93		6
839	Interferon- γ causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatum. 2017, 108, 45-53		7

838	Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders. 2017 , 31, 37-55	14
837	The role of anxious distress in immune dysregulation in patients with major depressive disorder. 2017 , 7, 1268	31
836	Effects of Shambhavi Mahamudra Kriya, a Multicomponent Breath-Based Yogic Practice (Pranayama), on Perceived Stress and General Well-Being. 2017 , 22, 788-797	23
835	The role of rare copy number variants in depression. 2017 , 27, S787-S788	
834	N-acetylcysteine as an adjunctive treatment to reduce depressive symptom severity when C-reactive protein levels are increased. 2017 , 27, S788	
833	Effect of agomelatine and escitalopram on emotional experiences in outpatients suffering from major depressive disorder. 2017 , 27, S788-S789	
832	Positive association between IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study. 2017 , 28, 185-194	8
831	White blood cell count at first depression diagnosis as predictor for risk of subsequent hospitalization with depression. 2017 , 26, 1-6	3
830	The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease. 2017 , 66, 156-164	46
829	Depressed gut? The microbiota-diet-inflammation triologue in depression. 2017 , 30, 369-377	62
828	Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. 2017 , 31, 1149-1165	113
827	Inflammation in Schizophrenia: What It Means and How to Treat It. 2017 , 25, 62-63	1
826	Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients. 2017 , 60, 136-141	20
825	Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses. 2017 , 8, 135-146	23
824	Depression in cancer: The many biobehavioral pathways driving tumor progression. 2017 , 52, 58-70	118
823	Current posttraumatic stress disorder and exaggerated threat sensitivity associated with elevated inflammation in the Mind Your Heart Study. 2017 , 60, 198-205	46
822	Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. 2017 , 10, 153-166	22
821	Sleep architecture parameters as a putative biomarker of suicidal ideation in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2017 , 208, 309-315	6.6 39

820	Sleep Health: Reciprocal Regulation of Sleep and Innate Immunity. 2017 , 42, 129-155	177
819	Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond. 2017 , 42, 254-270	275
818	Inflammation Effects on Motivation and Motor Activity: Role of Dopamine. 2017 , 42, 216-241	180
817	Genetic Contributions of Inflammation to Depression. 2017 , 42, 81-98	123
816	Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation. 2017 , 42, 334-359	76
815	Personalized medicine in psychiatry. 2017 , 71, 12-19	37
814	In Sickness and in Health: The Co-Regulation of Inflammation and Social Behavior. 2017 , 42, 242-253	158
813	Hidden Wounds? Inflammatory Links Between Childhood Trauma and Psychopathology. 2017 , 68, 517-544	125
812	The protective effects of resveratrol on social stress-induced cytokine release and depressive-like behavior. 2017 , 59, 147-157	54
811	Association of inflammation with specific symptoms of depression in a general population of older people: The English Longitudinal Study of Ageing. 2017 , 61, 27-30	42
810	Contributions of the adaptive immune system to mood regulation: Mechanisms and pathways of neuroimmune interactions. 2017 , 79, 49-57	20
809	Microglia Priming with Aging and Stress. 2017 , 42, 318-333	171
808	The chronic mild stress (CMS) model of depression: History, evaluation and usage. 2017 , 6, 78-93	394
807	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. <i>Journal of Affective Disorders</i> , 2017 , 207, 114-120	6.6 75
806	The role of macrophages in anti-inflammatory activity of antidepressant drugs. 2017 , 222, 823-830	44
805	Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma?. 2017 , 42, 99-114	166
804	Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study. 2017 , 59, 253-259	78
803	New medications for treatment-resistant depression: a brief review of recent developments. 2017 , 22, 39-48	9

802	Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis. 2017 , 20, 435-444		56
801	Predominant polarity in bipolar disorder [Is there a genetic base?]. 2017 , 27, S838-S839		1
800	Effect of the inflammatory biomarker C-reactive protein on response to lurasidone treatment in patients with bipolar depression. 2017 , 27, S839		
799	Bipolar disorder and white matter microstructure: ENIGMA bipolar disorder fractional anisotropy DTI results. 2017 , 27, S839-S840		3
798	Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination. 2017 , 20, 919-927		20
797	The hidden wounds of childhood trauma. 2017 , 8, 137584		6
796	Biomarkers for depression: recent insights, current challenges and future prospects. 2017 , 13, 1245-1262		159
795	Organ-Organ Crosstalk and Alcoholic Liver Disease. 2017 , 7,		19
794	Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications. <i>Brain Sciences</i> , 2017 , 7,	3.4	102
793	Resilience and Vulnerability to Pain and Inflammation in the Hippocampus. 2017 , 18,		19
792	Visceral Inflammation and Immune Activation Stress the Brain. 2017 , 8, 1613		38
791	Cytokines and depression in cancer patients and caregivers. 2017 , 13, 2903-2911		6
790	The renin-angiotensin system: a possible new target for depression. 2017 , 15, 144		65
789	Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. <i>Journal of Neuroinflammation</i> , 2017 , 14, 188	10.1	70
788	Neuroprotektive Ansätze bei der antidepressiven Behandlung. 2017 , 67, S23-S24		
787	AN EXPERIMENTAL STUDY EVALUATING THE INFLUENCE OF BISPHOSPHONATES ON DEPRESSION PATTERNS IN SWISS ALBINO MICE AND WISTER RATS. 2017 , 9, 187		0
786	Is there a link between TNF gene expression and cognitive deficits in depression?. 2017 , 64, 65-73		24
785	Neuroinflammation and Neurotransmission Mechanisms Involved in Neuropsychiatric Disorders. 2017 ,		2

784	Maternal Deprivation?. 2017 ,		4
783	Neuroendocrine and Neurochemical Processes in Depression. 2017 , 189-200		1
782	Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia. 2018 , 4, 4		22
781	Metabolism, Metabolomics, and Inflammation in Posttraumatic Stress Disorder. 2018 , 83, 866-875		77
780	Presentation and Neurobiology of Anhedonia in Mood Disorders: Commonalities and Distinctions. 2018 , 20, 13		14
779	Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. 2018 , 70, 61-75		223
778	Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: An electronic health record-based study. 2018 , 91, 226-234		46
777	TNF- α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. 2018 , 199, 281-284		58
776	Anhedonia in depression: biological mechanisms and computational models. 2018 , 22, 128-135		51
775	Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression. 2018 , 90, 212-220		23
774	Elevated tumor necrosis factor-alpha receptor subtype 1 and the association with abnormal brain function in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018 , 235, 250-256	6.6	10
773	Biomarkers as Common Data Elements for Symptom and Self-Management Science. 2018 , 50, 276-286		20
772	Neuroimmune Biomarkers in Mental Illness. 2018 , 40, 45-78		21
771	Effects of psychological interventions on systemic levels of inflammatory biomarkers in humans: A systematic review and meta-analysis. 2018 , 74, 68-78		25
770	Inflammatory cytokines and depression in children with cancer: A review of the literature. 2018 , 35, 11-19		1
769	Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations. 2018 , 44, 973-982		196
768	Novel Therapeutics in Bipolar Disorder. <i>Current Treatment Options in Psychiatry</i> , 2018 , 5, 162-181	3.1	1
767	TNF α disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. 2018 , 69, 556-567		87

766	Association between increased serum interleukin-6 levels and sustained attention deficits in patients with major depressive disorder. 2018 , 48, 2508-2514	20
765	Effects of anti-inflammatory drugs on the expression of tryptophan-metabolism genes by human macrophages. 2018 , 103, 681-692	15
764	Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target. 2018 , 87, 56-66	37
763	Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2 \times double-blind, randomized, placebo-controlled, phase IIA clinical trial. 2018 , 8, 27	79
762	Unpacking Major Depressive Disorder: From Classification to Treatment Selection. 2018 , 63, 308-313	7
761	Deciphering sex differences in the immune system and depression. 2018 , 50, 67-90	34
760	The use of quetiapine in the treatment of major depressive disorder: Evidence from clinical and experimental studies. 2018 , 86, 36-50	13
759	Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. 2018 , 8, 10	32
758	Interoception and Inflammation in Psychiatric Disorders. 2018 , 3, 514-524	41
757	Antidepressant Therapy for Depression: An Update. 2018 , 241-255	
756	Neurobiology and Evidence-Based Review on Novel Therapeutic Strategy for Treatment-Resistant Depression (TRD). 2018 , 269-275	1
755	Diagnosis of Major Depressive Disorders: Clinical and Biological Perspectives. 2018 , 53-68	1
754	Modulating Microglial Activation As a Possible Therapeutic Target for Depression. 2018 , 209-219	
753	Precision Psychiatry: Personalized Clinical Approach to Depression. 2018 , 245-261	
752	TNF α -dependent anhedonia and upregulation of hippocampal serotonin transporter activity in a mouse model of collagen-induced arthritis. 2018 , 137, 211-220	9
751	Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study. 2018 , 57, 1381-1389	28
750	Blood biomarkers and treatment response in major depression. 2018 , 18, 513-529	31
749	Effects of adjunctive N-acetylcysteine on depressive symptoms: Modulation by baseline high-sensitivity C-reactive protein. 2018 , 263, 268-274	19

748	Tryptophan catabolites along the indoleamine 2,3-dioxygenase pathway as a biological link between depression and cancer. 2018 , 29, 165-180		15
747	Depressive symptoms in obesity: Relative contribution of low-grade inflammation and metabolic health. 2018 , 91, 55-61		30
746	Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. 2018 , 23, 335-343		310
745	Depressive disorders: Processes leading to neurogeneration and potential novel treatments. 2018 , 80, 189-204		29
744	Genome-wide analysis of LPS-induced inflammatory response in the rat ventral hippocampus: Modulatory activity of the antidepressant agomelatine. 2018 , 19, 390-401		8
743	Microglial recruitment of IL-1 β -producing monocytes to brain endothelium causes stress-induced anxiety. 2018 , 23, 1421-1431		157
742	IDO chronic immune activation and tryptophan metabolic pathway: A potential pathophysiological link between depression and obesity. 2018 , 80, 234-249		44
741	Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. <i>Journal of Affective Disorders</i> , 2018 , 233, 3-14	6.6	67
740	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia. 2018 , 43, 1317-1323		52
739	Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. <i>Journal of Affective Disorders</i> , 2018 , 227, 219-225	6.6	92
738	Nested positive feedback loops in the maintenance of major depression: An integration and extension of previous models. 2018 , 67, 374-397		21
737	Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities. 2018 , 58, 411-428		51
736	Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder. <i>Journal of Affective Disorders</i> , 2018 , 225, 593-598	6.6	26
735	Metabolic and inflammatory markers: associations with individual depressive symptoms. 2018 , 48, 1102-1110		80
734	Immune-based strategies for mood disorders: facts and challenges. 2018 , 18, 139-152		50
733	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. 2018 , 30, 297-305		8
732	Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. 2018 , 69, 264-272		65
731	Cytokine alterations in panic disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2018 , 228, 91-96	6.6	40

730	Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. 2018 , 83, 61-69	184
729	Impact, Diagnosis, Phenomenology, and Biology. 2019 , 250, 3-33	
728	A Case Series for Salmonella Carriers Who Presented with Psychosomatic Depressive Disorder and Showed Improvement after Ceftriaxone Treatment for 15 Days. 2018 , 07,	
727	PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. 2018 , 8, 57	104
726	De ontstoken geest. 2018 , 22, 186-192	1
725	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. 2018 , 19,	85
724	Correlation of clinical features with hs-CRP in TRD patients. 2019 , 17, 344-348	0
723	Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder. 2017 , 16, 891-899	15
722	Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. 2018 , 8, 337-348	32
721	Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders. 2018 , 11, 211-222	17
720	Obesity moderates the complex relationships between inflammation, oxidative stress, sleep quality and depressive symptoms. 2018 , 5, 32	9
719	Clemastine Alleviates Depressive-Like Behavior Through Reversing the Imbalance of Microglia-Related Pro-inflammatory State in Mouse Hippocampus. 2018 , 12, 412	29
718	Neuroimmune and Inflammatory Signals in Complex Disorders of the Central Nervous System. 2018 , 25, 246-270	31
717	The art of medicine: Inflamed depression. 2018 , 392, 1189-1190	21
716	Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. 2018 , 8, e025333	37
715	Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. 2018 , 98, 222-229	30
714	Inflammation and Depression: the Neuroimmune Connection. <i>Current Treatment Options in Psychiatry</i> , 2018 , 5, 452-458	3.1 8
713	Role of Inflammation in Depression and Treatment Implications. 2019 , 250, 255-286	28

712	Evaluating the Effect of Coenzyme Q10 Augmentation on Treatment of Bipolar Depression: A Double-Blind Controlled Clinical Trial. 2018 , 38, 460-466	31
711	Neural mechanisms of emotion regulation and their role in endocrine and immune functioning: A review with implications for treatment of affective disorders. 2018 , 95, 508-514	16
710	Elevation of tumor necrosis factor alpha levels is associated with restless legs symptoms in clinically depressed patients. 2018 , 115, 1-5	4
709	Involvement of Innate and Adaptive Immune Systems Alterations in the Pathophysiology and Treatment of Depression. 2018 , 12, 547	41
708	N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial. 2018 , 18, 279	15
707	Effects of Peripheral Immune Challenge on In Vivo Firing of Basolateral Amygdala Neurons in Adult Male Rats. 2018 , 390, 174-186	12
706	The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. 2018 , 87, 331-339	24
705	The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. 2018 , 94, 219-237	71
704	Correlation between Depression, Posttraumatic Stress Disorder, and Inflammatory Factors in Patients with Severe Burn Injury. 2018 , 84, 1350-1354	4
703	Immunization with Mycobacterium vaccae induces an anti-inflammatory milieu in the CNS: Attenuation of stress-induced microglial priming, alarmins and anxiety-like behavior. 2018 , 73, 352-363	48
702	Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. 2018 , 24, 1471-1480	43
701	Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. 2018 , 95, 43-49	117
700	Influences and Impact of Anxiety and Depression in the Setting of Inflammatory Bowel Disease. 2018 , 24, 2303-2308	40
699	Stress-induced pro- and anti-inflammatory cytokine concentrations in panic disorder patients. 2018 , 94, 31-37	13
698	Childhood Microbial Experience, Immunoregulation, Inflammation, and Adult Susceptibility to Psychosocial Stressors and Depression. 2018 , 17-44	3
697	Pathways Driving Neuroprogression in Depression: The Role of Immune Activation. 2018 , 173-198	1
696	Neuroimmunopharmacology at the Interface of Inflammation and Pharmacology Relevant to Depression. 2018 , 223-240	
695	Does Inflammation Link Clinical Depression and Coronary Artery Disease?. 2018 , 393-409	

694	Inflammation in Bipolar Disorder. 2018 , 445-454		3
693	Depression Subtypes and Inflammation: Atypical Rather Than Melancholic Depression Is Linked With Immunometabolic Dysregulations. 2018 , 455-471		1
692	Inflammation as a Marker of Clinical Response to Treatment: A Focus on Treatment-Resistant Depression. 2018 , 473-487		1
691	Clinical Trials of Anti-Inflammatory Treatments of Major Depression. 2018 , 489-507		2
690	Efficacy of Anti-Inflammatory Treatment in Depression. 2018 , 525-538		1
689	Future Perspectives on Immune-Related Treatments. 2018 , 589-604		
688	Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression. 2018 , 39, 1463-1472		25
687	Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities. 2018 , 124, 3990-3999		41
686	Sex differences in how inflammation affects behavior: What we can learn from experimental inflammatory models in humans. 2018 , 50, 91-106		41
685	References. 2018 , 555-664		
684	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. 2018 , 94, 11-16		53
683	Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. 2018 , 15, 505-522		802
682	Peripheral Etanercept Administration Normalizes Behavior, Hippocampal Neurogenesis, and Hippocampal Reelin and GABA Receptor Expression in a Preclinical Model of Depression. 2018 , 9, 121		21
681	Altered Resting-State Brain Activities in Drug-Naïve Major Depressive Disorder Assessed by fMRI: Associations With Somatic Symptoms Defined by - Theory of the Traditional Chinese Medicine. <i>Frontiers in Psychiatry</i> , 2018 , 9, 195	5	7
680	Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. 2018 , 98, 477-504		339
679	Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation. 2018 , 19,		46
678	Depression in people with type 2 diabetes: current perspectives. 2018 , 11, 333-343		44
677	Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study). <i>Frontiers in Psychiatry</i> , 2018 , 9, 326	5	10

676	Novel treatment options in depression and psychosis. 2018 , 14, 741-747		29
675	Regulatory T Cells As Supporters of Psychoimmune Resilience: Toward Immunotherapy of Major Depressive Disorder. <i>Frontiers in Neurology</i> , 2018 , 9, 167	4.1	20
674	A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice. 2018 , 97, 120-130		36
673	Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. 2018 , 73, 115-124		53
672	Neuron-related blood inflammatory markers as an objective evaluation tool for major depressive disorder: An exploratory pilot case-control study. <i>Journal of Affective Disorders</i> , 2018 , 240, 88-98	6.6	27
671	The Chinese Medicine Wu-Tou Decoction Relieves Neuropathic Pain by Inhibiting Hippocampal Microglia Activation. <i>Scientific Reports</i> , 2018 , 8, 12292	4.9	6
670	Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review. <i>Journal of Affective Disorders</i> , 2018 , 241, 519-532	6.6	95
669	Emerging role of the P2X7-NLRP3-IL1 β pathway in mood disorders. 2018 , 98, 95-100		44
668	Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression. 2018 , 12, 498		24
667	C-reactive protein and response to lurasidone in patients with bipolar depression. 2018 , 73, 717-724		21
666	Resilience and immunity. 2018 , 74, 28-42		80
665	Resolution of inflammation and mood disorders. 2018 , 105, 190-201		19
664	Whole-Body Heating: An Emerging Therapeutic Approach to Treatment of Major Depressive Disorder. 2018 , 16, 259-265		3
663	Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. 2018 , 99, 914-924.e3		83
662	Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. 2018 , 19, 447		29
661	An Integrative Approach to Neuroinflammation in Psychiatric disorders and Neuropathic Pain. 2018 , 12, 1179069518793639		39
660	Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study. 2018 , 269, 207-211		56
659	Brain Kynurenine and BH4 Pathways: Relevance to the Pathophysiology and Treatment of Inflammation-Driven Depressive Symptoms. 2018 , 12, 499		33

658	Antenatal depression, psychotropic medication use, and inflammation among pregnant women. 2018 , 21, 785-790	9
657	The Impact of Targeted Rheumatoid Arthritis Pharmacologic Treatment on Mental Health: A Systematic Review and Network Meta-Analysis. 2018 , 70, 1377-1391	27
656	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. 2018 , 30, 1-7	19
655	Biomarkers for Depression: Recent Insights, Current Challenges and Future Prospects. 2018 , 16, 194-209	9
654	International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. 2018 , 70, 475-504	31
653	Principles of inflammasome priming and inhibition: Implications for psychiatric disorders. 2018 , 73, 66-84	42
652	Treatment-resistant depression and peripheral C-reactive protein. 2019 , 214, 11-19	152
651	[Major depression and liver disease: the role of microbiome and inflammation]. 2019 , 87, 12-21	2
650	Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. 2019 , 10, 58-78	9
649	Inflaming sex differences in mood disorders. 2019 , 44, 184-199	45
648	JHU-083 selectively blocks glutaminase activity in brain CD11b cells and prevents depression-associated behaviors induced by chronic social defeat stress. 2019 , 44, 683-694	27
647	Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect. 2019 , 56, 3484-3500	28
646	The Future of Psychoneuroimmunology: Promises and Challenges. 2019 , 235-266	3
645	Inflammation in psychiatric disorders: what comes first?. 2019 , 1437, 57-67	165
644	The Role of Inflammation in Depression and Fatigue. 2019 , 10, 1696	144
643	Elevated hs-CRP level is associated with depression in younger adults: Results from the Korean National Health and Nutrition Examination Survey (KNHANES 2016). 2019 , 109, 104397	7
642	Mechanisms and treatment of late-life depression. 2019 , 9, 188	125
641	Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. 2019 , 9, 182	35

640	Involvement of inflammatory gene expression pathways in depressed patients with hyperphagia. 2019 , 9, 193		8
639	Sphingosine-1-phosphate receptor 3 in the medial prefrontal cortex promotes stress resilience by reducing inflammatory processes. 2019 , 10, 3146		13
638	Neurologic and Psychiatric Effects of Cytokines and Targeted Biological Therapies. 2019 , 269-283		
637	Depression/anxiety symptoms in axial spondyloarthritis and psoriatic arthritis patients in Serbia: a pilot study. 2019 , 39, 1595-1605		6
636	Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study. <i>Journal of Affective Disorders</i> , 2019 , 256, 509-516	6.6	10
635	Commentary: Depression and Incidence of Frailty in Older People From Six Latin American Countries by Prina et al. 2019 , 27, 1080-1082		1
634	Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review. <i>Journal of Affective Disorders</i> , 2019 , 257, 640-649	6.6	41
633	Andrographolide triggers autophagy-mediated inflammation inhibition and attenuates chronic unpredictable mild stress (CUMS)-induced depressive-like behavior in mice. 2019 , 379, 114688		40
632	Influence of adjuvant Coenzyme Q10 on inflammatory and oxidative stress biomarkers in patients with bipolar disorders during the depressive episode. 2019 , 46, 5333-5343		8
631	Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management. 2019 , 21, 650-659		17
630	Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. <i>Frontiers in Psychiatry</i> , 2019 , 10, 458	5	61
629	Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders. 2019 , 236, 3063-3079		94
628	Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. 2019 , 81, 361-373		38
627	New Approaches in Translational Medicine for Phase I Clinical Trials of CNS Drugs. 2019 , 29, 81-91		0
626	Translational Medicine Strategies in Drug Development for Mood Disorders. 2019 , 29, 333-347		
625	Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. 2019 , 49, 1958-1970		162
624	The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. 2019 , 4, 632-642		66
623	Mechanism of Action of ECT. 2019 , 13-23		2

622	Kynurenine metabolism and inflammation-induced depressed mood: A human experimental study. 2019 , 109, 104371	15
621	Mindfulness meditation and improvement in depressive symptoms among Spanish- and English speaking adults: A randomized, controlled, comparative efficacy trial. 2019 , 14, e0219425	5
620	Peripheral Biomarkers of Inflammation in Depression: Evidence from Animal Models and Clinical Studies. 2019 , 2011, 467-492	5
619	On-treatment improvement of an emerging psychosomatic depressive disorder among salmonella carriers: a multicenter experience from Egypt. 2019 , 12, 2573-2582	1
618	Externalizing trajectories predict elevated inflammation among adolescents exposed to early institutional rearing: A randomized clinical trial. 2019 , 109, 104408	5
617	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. 2019 , 9, 254	18
616	On the Duty to Implement European Framework Agreements: Lessons to be Learned from the Hairdressers Case. 2019 ,	2
615	No Go World: How Fear Is Redrawing Our Maps and Infecting Our Politics. By Ruben Andersson. 2019 ,	
614	Unusual osseous metaplasia following hernia repair with Prolene mesh: a case report. 2019 , 2019, rjz251	
613	The Immune-Mind Connection. 2019 , 179, 803-805	3
612	Antidepressant active ingredients from herbs and nutraceuticals used in TCM: pharmacological mechanisms and prospects for drug discovery. 2019 , 150, 104520	53
611	Inflammation and Risk of Depression in HIV: Prospective Findings From the Multicenter AIDS Cohort Study. 2019 , 188, 1994-2003	11
610	Tumor necrosis factor receptor 2: A potential target for antidepressant drug development. 2019 , 10, 272-282	
609	ANZJP this month September 2019: Acculturating the brain?. 2019 , 53, 833-834	
608	Juvenile Arthritis Patients Suffering from Chronic Inflammation Have Increased Activity of Both IDO and GTP-CH1 Pathways But Decreased BH4 Efficacy: Implications for Well-Being, Including Fatigue, Cognitive Impairment, Anxiety, and Depression. 2019 , 12,	13
607	Symptoms of Depression and Risk of Abdominal Aortic Aneurysm: A HUNT Study. 2019 , 8, e012535	7
606	Remicade (infliximab): 20 years of contributions to science and medicine. 2019 , 13, 139-178	36
605	Microbiome and Mental Health, Specifically as It Relates to Adolescents. 2019 , 21, 93	14

604	The formative role of microglia in stress-induced synaptic deficits and associated behavioral consequences. 2019 , 711, 134369		12
603	Baseline cortisol and the efficacy of antigluocorticoid treatment in mood disorders: A meta-analysis. 2019 , 110, 104420		13
602	Blocking the trigger: An integrative view on the anti-inflammatory therapy of depression. 2019 , 82, 10-12		4
601	The Importance of Psychoneuroimmunology for Social Workers. 2019 , 100, 17-33		
600	COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2019 , 10, 375	5	42
599	SCI and depression: Does inflammation commandeer the brain?. 2019 , 320, 112977		6
598	Major depressive disorders accompanying autoimmune diseases - Response to treatment. 2019 , 95, 109678		6
597	Psychosis as an adverse effect of monoclonal antibody immunotherapy. 2019 , 81, 646-649		10
596	Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia. 2020 , 44, 49-66		51
595	Effects of restraint stress on the regulation of hippocampal glutamate receptor and inflammation genes in female C57BL/6 and BALB/c mice. 2019 , 10, 100169		8
594	Fast Green FCF Attenuates Lipopolysaccharide-Induced Depressive-Like Behavior and Downregulates TLR4/Myd88/NF- κ B Signal Pathway in the Mouse Hippocampus. 2019 , 10, 501		14
593	Education about Mental Health and Illness. 2019 ,		
592	An immune gate of depression - Early neuroimmune development in the formation of the underlying depressive disorder. 2019 , 71, 1299-1307		21
591	Unraveling the complex interplay of immunometabolic systems that contribute to the neuroprogression of psychiatric disorders. 2019 , 32, 111-121		5
590	Teaching Neurobiology in Psychiatry. 2019 , 185-211		1
589	Implications for Reward Processing in Differential Responses to Loss: Impacts on Attachment Hierarchy Reorganization. 2019 , 23, 391-405		14
588	Inflammation in Tic Disorders and Obsessive-Compulsive Disorder: Are PANS and PANDAS a Path Forward?. 2019 , 34, 598-611		22
587	Diabetes, depressive symptoms, and mortality risk in old age: The role of inflammation. 2019 , 36, 941-949		8

586	Biomarker-Guided Anti-inflammatory Therapies: From Promise to Reality Check. <i>JAMA Psychiatry</i> , 2019 , 76, 779-780	14.5	13
585	Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2019 , 76, 783-790	14.5	83
584	Systemic Inhibition of Soluble Tumor Necrosis Factor with XPro1595 Exacerbates a Post-Spinal Cord Injury Depressive Phenotype in Female Rats. 2019 , 36, 2964-2976		5
583	The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: A systematic review of randomized clinical trials. 2019 , 207, 104-112		5
582	Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. 2019 , 33, 685-694		6
581	Sex-specific roles of cellular inflammation and cardiometabolism in obesity-associated depressive symptomatology. 2019 , 43, 2045-2056		6
580	Inflammation and decreased functional connectivity in a widely-distributed network in depression: Centralized effects in the ventral medial prefrontal cortex. 2019 , 80, 657-666		45
579	Supraspinal neuroimmune crosstalk in chronic pain states. 2019 , 11, 7-15		7
578	Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia. 2020 , 44, 227-244		20
577	The Influence of Antidepressants on the Immune System. 2019 , 67, 143-151		37
576	Neuroimmune Aspects of Alcoholism and Affective Comorbidity. 2019 , 179-186		
575	Curcumin in Depressive Disorders. 2019 , 459-477		
574	Challenges and opportunities of a-priori and a-posteriori variability in maternal immune activation models. 2019 , 28, 119-128		19
573	miR-155 mediates inflammatory injury of hippocampal neuronal cells via the activation of microglia. 2019 , 19, 2627-2635		16
572	Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. 2019 , 139, 404-419		143
571	Inflammatory Proteins Predict Change in Depressive Symptoms in Male and Female Adolescents. 2019 , 7, 754-767		28
570	Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes. <i>Frontiers in Psychiatry</i> , 2019 , 10, 57	5	54
569	Opportunities in precision psychiatry using PET neuroimaging in psychosis. 2019 , 131, 104428		5

568	Reversal of a Treatment-Resistant, Depression-Related Brain State with the Kv7 Channel Opener Retigabine. 2019 , 406, 109-125		9
567	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. 2020 , 182, 130-137		24
566	Immunoneuropsychiatry - novel perspectives on brain disorders. 2019 , 15, 317-328		141
565	Interplay between pro-inflammatory cytokines, childhood trauma, and executive function in depressed adolescents. 2019 , 114, 1-10		21
564	Can't or Won't? Immunometabolic Constraints on Dopaminergic Drive. 2019 , 23, 435-448		50
563	Sex Differences in the Relationship Between Inflammation and Reward Sensitivity: A Randomized Controlled Trial of Endotoxin. 2019 , 4, 619-626		20
562	Somatization, Depression, and Anxiety Disorders in a Rhinology Practice. 2019 , 33, 470-477		5
561	Leptin Prevents Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of Dopamine Receptors. <i>Frontiers in Psychiatry</i> , 2019 , 10, 125	5	24
560	Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists. 2019 , 236, 2899-2907		2
559	Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. 2019 , 23, 2324-2332		172
558	Deficiencies of microglia and TNF α in the mPFC-mediated cognitive inflexibility induced by social stress during adolescence. 2019 , 79, 256-266		18
557	A clinical model for identifying an inflammatory phenotype in mood disorders. 2019 , 113, 148-158		10
556	Central and Peripheral Inflammation Link Metabolic Syndrome and Major Depressive Disorder. 2019 , 34, 123-133		57
555	Exploring the Potential Antidepressant Mechanisms of TNF α Antagonists. 2019 , 13, 98		22
554	Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior. 2019 , 236, 2975-2982		11
553	The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC. 2019 , 1-8		
552	Obesity and Depression: Shared Pathophysiology and Translational Implications. 2019 , 169-183		2
551	Novel Therapeutic Targets for Major Depressive Disorder. 2019 , 383-400		

550	Targeting the immune system in the treatment of bipolar disorder. 2019 , 236, 2909-2921		27
549	Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?. 2019 , 197, 308-318		34
548	High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. 2019 , 9, 303		36
547	C-reactive protein is associated with cognitive performance in a large cohort of euthymic patients with bipolar disorder. 2021 , 26, 4096-4105		13
546	P.335 Relationship between inflammation biomarkers and improvement of depression: A pilot study. 2019 , 29, S239-S240		
545	Depression And Anxiety In Patients With Juvenile Idiopathic Arthritis: Current Insights And Impact On Quality Of Life, A Systematic Review. 2019 , 11, 237-252		25
544	The 'Yin' and the 'Yang' of the kynurenine pathway: excitotoxicity and neuroprotection imbalance in stress-induced disorders. 2019 , 30, 163-186		11
543	Inflammation, infection and depression: an evolutionary perspective. 2019 , 1,		
542	Depression, GABA, and Age Correlate with Plasma Levels of Inflammatory Markers. 2019 , 20,		5
541	Actualizaci3n cl3nica de los trastornos depresivos. 2019 , 12, 5041-5051		
540	Cytokine Alterations in Schizophrenia: An Updated Review. <i>Frontiers in Psychiatry</i> , 2019 , 10, 892	5	82
539	Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. 2019 , 45, 742-751		71
538	Revisiting inflammation in bipolar disorder. 2019 , 177, 12-19		59
537	Neuroimmune signaling in alcohol use disorder. 2019 , 177, 34-60		71
536	The association between low-grade inflammation and the clinical features of bipolar disorder in Han Chinese population. 2019 , 101, 286-294		11
535	Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics. <i>Frontiers in Psychiatry</i> , 2018 , 9, 753	5	36
534	Psoriasis and Depression: The Role of Inflammation. 2019 , 110, 12-19		22
533	Psoriasis and Depression: The Role of Inflammation. 2019 , 110, 12-19		7

532	Treatment-Resistant Depression: Understandings on the Neurobiological Etiology that Lead to Novel Pharmacological Treatment Options. 2019 , 99-107	
531	Longitudinal association between inflammatory markers and specific symptoms of depression in a prospective birth cohort. 2019 , 76, 74-81	53
530	Cognitive impairment in major depressive disorder. 2019 , 24, 22-29	40
529	History of major depression is associated with neuropsychiatric symptoms but not systemic inflammation in a cross-sectional study in obese patients. 2019 , 76, 215-222	0
528	Moderators for depressed mood and systemic and transcriptional inflammatory responses: a randomized controlled trial of endotoxin. 2019 , 44, 635-641	18
527	Plasma and cerebrospinal fluid inflammatory cytokines in perinatal depression. 2019 , 220, 271.e1-271.e10	18
526	Longitudinal Association Between Depression and Inflammatory Markers: Results From the Netherlands Study of Depression and Anxiety. 2019 , 85, 829-837	72
525	Anxiety in obesity: Is neuroinflammation the critical link?. 2019 , 78, 7-8	1
524	Rheumatoid arthritis and depression: an inflammatory perspective. 2019 , 6, 164-173	125
523	Old Friends, immunoregulation, and stress resilience. 2019 , 471, 237-269	29
522	Finding narrative in a scientific field: Understanding the relationship between the immune system and psychiatric illness. 2019 , 77, 1-2	1
521	Psoriasis and suicidality: A review of the literature. 2019 , 32, e12771	17
520	Personalized Medicine. 2019 , 109-121	0
519	Interleukin-6 Induced by Social Stress Promotes a Unique Transcriptional Signature in the Monocytes That Facilitate Anxiety. 2019 , 85, 679-689	39
518	The Role of Depressive Subtypes within the Neuroinflammation Hypothesis of Major Depressive Disorder. 2019 , 403, 93-110	65
517	Depression and obesity: evidence of shared biological mechanisms. 2019 , 24, 18-33	237
516	Blood-based biomarkers predicting response to antidepressants. 2019 , 126, 47-63	13
515	Longitudinal changes of inflammatory biomarkers moderate the relationship between recent stressful life events and prospective symptoms of depression in a diverse sample of urban adolescents. 2020 , 86, 43-52	12

514	What does plasma CRP tell us about peripheral and central inflammation in depression?. 2020 , 25, 1301-1311	131
513	Cytokine concentrations are related to level of mental distress in inpatients not using anti-inflammatory drugs. 2020 , 32, 23-31	4
512	Circulating versus lipopolysaccharide-induced inflammatory markers as correlates of subthreshold depressive symptoms in older adults. 2020 , 21, 634-641	3
511	Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far. 2020 , 83, 7-21	44
510	EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. 2020 , 59, 2439-2447	6
509	Inflammation and the dimensions of depression: A review. 2020 , 56, 100800	50
508	Association of Prospective Risk for Chronic PTSD Symptoms With Low TNF α and IFN γ Concentrations in the Immediate Aftermath of Trauma Exposure. 2020 , 177, 58-65	33
507	Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. 2020 , 25, 1275-1285	54
506	Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience. 2020 , 135, 104578	20
505	Longitudinal population subgroups of CRP and risk of depression in the ALSPAC birth cohort. 2020 , 96, 152143	4
504	Posttraumatic Stress Disorder and Inflammation: Untangling Issues of Bidirectionality. 2020 , 87, 885-897	24
503	Beyond depression: the expanding role of inflammation in psychiatric disorders. 2020 , 19, 108-109	40
502	C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. 2020 , 84, 269-274	9
501	Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis. 2020 , 188, 172838	10
500	Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD. 2020 , 25, 750-764	4
499	Neuroimaging biomarkers of late-life major depressive disorder pathophysiology, pathogenesis, and treatment response. 2020 , 339-356	
498	Peripheral Blood Cell-Stratified Subgroups of Inflamed Depression. 2020 , 88, 185-196	50
497	Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT). 2020 , 22, 225	1

496	Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - A comprehensive systematic review and meta-analysis. 2020 , 90, 364-380		25
495	Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis. 2021 , 26, 3430-3443		18
494	Präklinische Einblicke in das Zusammenspiel von Mikrobiota und Verhalten. 2020 , 39, 19-25		
493	Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System. 2020 , 34, 1229-1251		15
492	Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. 2020 , 102, 152195		2
491	Neuroinflammation. 2020 , 175, 235-259		8
490	Application of antidepressants in depression: A systematic review and meta-analysis. 2020 , 80, 169-181		9
489	Convergent Functional Genomics approach to prioritize molecular targets of risk in early life stress-related psychiatric disorders. <i>Brain, Behavior, & Immunity - Health</i> , 2020 , 8, 100120	5.1	2
488	Old Friends Immunoregulation und Stressresilienz. 2020 , 39, 55-66		
487	Economic Hardship, Ocular Complications, and Poor Self-reported Visual Function are Predictors of Mental Problems in Patients with Uveitis. 2020 , 1-11		0
486	Major Depressive Disorder Is Associated With Differential Expression of Innate Immune and Neutrophil-Related Gene Networks in Peripheral Blood: A Quantitative Review of Whole-Genome Transcriptional Data From Case-Control Studies. 2020 , 88, 625-637		21
485	Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort. 2021 , 143, 534-542		3
484	Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management. 2020 , 12, 1759720X20970028		4
483	Peripheral Markers of Depression. 2020 , 9,		37
482	Curcumin in Depression: Potential Mechanisms of Action and Current Evidence-A Narrative Review. <i>Frontiers in Psychiatry</i> , 2020 , 11, 572533	5	14
481	Sex Differences in the Inflammatory Consequences of Stress: Implications for Pharmacotherapy. 2020 , 375, 161-174		8
480	Neuroinflammatory alterations in trait anxiety: modulatory effects of minocycline. 2020 , 10, 256		13
479	Synergistic effects of low-level stress and a Western diet on metabolic homeostasis, mood, and myocardial ischemic tolerance. 2020 , 319, R347-R357		6

478	The genetic double whammy - Autoimmune and mental health disorders. 2020 , 89, 7-8		
477	Study Protocol for Teen Inflammation Glutamate Emotion Research (TIGER). 2020 , 14, 585512		5
476	Old Friends – Immunoregulation und Stressresilienz. 2020 , 39, 47-54		
475	C-Reactive Protein: Marker of risk for post-traumatic stress disorder and its potential for a mechanistic role in trauma response and recovery. 2020 ,		8
474	Sick for science: experimental endotoxemia as a translational tool to develop and test new therapies for inflammation-associated depression. 2021 , 26, 3672-3683		21
473	Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications. 2020 , 45, 2229-2238		9
472	Treatment Response Biomarkers in Anxiety Disorders: From Neuroimaging to Neuronally-Derived Extracellular Vesicles and Beyond. 2020 , 3,		2
471	Affective Immunology: The Crosstalk Between Microglia and Astrocytes Plays Key Role?. 2020 , 11, 1818		10
470	Childhood trauma, suicide risk and inflammatory phenotypes of depression: insights from monocyte gene expression. 2020 , 10, 296		16
469	The Innate Immune System and Inflammatory Priming: Potential Mechanistic Factors in Mood Disorders and Gulf War Illness. <i>Frontiers in Psychiatry</i> , 2020 , 11, 704	5	8
468	The Inflamed Brain in Schizophrenia: The Convergence of Genetic and Environmental Risk Factors That Lead to Uncontrolled Neuroinflammation. 2020 , 14, 274		33
467	Sex-specific peripheral and central responses to stress-induced depression and treatment in a mouse model. 2020 , 98, 2541-2553		4
466	Trial failures of anti-inflammatory drugs in depression. 2020 , 7, 837		11
465	Microglial Activation and Response to Anti-inflammatory Treatment in Major Depressive Disorder: Another Piece in the Inflammation-Mood Disorders Puzzle. 2020 , 88, 594-596		2
464	Can precision medicine advance psychiatry?. 2021 , 38, 163-168		3
463	Higher inflammation and cerebral white matter injury associated with cognitive deficit in asthmatic patients with depression. 2020 , 1-15		0
462	Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV. <i>Brain, Behavior, & Immunity - Health</i> , 2020 , 7, 100121	5.1	6
461	Exposure to adversity and inflammatory outcomes in mid and late childhood. <i>Brain, Behavior, & Immunity - Health</i> , 2020 , 9, 100146	5.1	2

460	Investigating the Convergent Mechanisms between Major Depressive Disorder and Parkinson's Disease. 2021 , 6, 47-61		2
459	Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines -two case reports. <i>Brain, Behavior, & Immunity - Health</i> , 2020 , 9, 100173	5.1	15
458	Depresión e inflamación: ¿Una relación más allá del azar?. 2020 , 31, 188-196		
457	Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression. 2020 , 88, 193-202		6
456	Bidirectional Associations Between Inflammatory Biomarkers and Depressive Symptoms in Adolescents: Potential Causal Relationships. 2020 , 8, 690-703		25
455	Association of Childhood Trauma Exposure with Inflammatory Biomarkers Among Midlife Women. 2020 , 29, 1540-1546		7
454	Drugs to Treat Depression. 2020 , 227-267		
453	Proteomic Profiling as a Diagnostic Biomarker for Discriminating Between Bipolar and Unipolar Depression. <i>Frontiers in Psychiatry</i> , 2020 , 11, 189	5	5
452	Antidepressive properties of macrophage-colony stimulating factor in a mouse model of depression induced by chronic unpredictable stress. 2020 , 172, 108132		5
451	Is there neuroinflammation in depression? Understanding the link between the brain and the peripheral immune system in depression. 2020 , 152, 23-40		18
450	Inflammation and depression treatment response to electroconvulsive therapy: Sex-specific role of interleukin-8. 2020 , 89, 59-66		7
449	Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms. 2021 , 26, 5150-5160		10
448	Social integration and inflammation in individuals with and without posttraumatic stress disorder. 2020 , 89, 168-174		2
447	The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. 2020 , 17, 1897-1906		14
446	Inflammation as a treatment target in mood disorders: review. 2020 , 6, e60		20
445	The Bidirectional Relationship of Depression and Inflammation: Double Trouble. 2020 , 107, 234-256		205
444	Ongoing Research on the Role of Gintonin in the Management of Neurodegenerative Disorders. 2020 , 9,		15
443	Depression and Obesity: Analysis of Common Biomarkers. 2020 , 8,		14

442	Association between Dietary Inflammatory Index (DII [®]) and depression and anxiety in the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) Study population. 2020 , 20, 282		10
441	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. 2020 , 37, 771-783		5
440	Inflammatory cytokines in patients with common mental disorders treated with cognitive behavior therapy. <i>Brain, Behavior, & Immunity - Health</i> , 2020 , 3, 100045	5.1	2
439	GSK3 β A Master Player in Depressive Disorder Pathogenesis and Treatment Responsiveness. 2020 , 9,		19
438	The cytokine network in the pathogenesis of major depressive disorder. Close to translation?. 2020 , 19, 102504		27
437	Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. <i>Frontiers in Psychiatry</i> , 2020 , 11, 46	5	23
436	Could Suicide Be Fostered Through the Potential Antidepressant Mechanism of Biological Agents? A Psychodermatological Approach to Existing Bibliography. 2020 , 5, 46-51		
435	Tryptophan Metabolic Pathways Are Altered in Obesity and Are Associated With Systemic Inflammation. 2020 , 11, 557		43
434	Inflammation (IL-1 β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study. 2020 , 12,		6
433	Identifying Immunophenotypes of Inflammation in Depression: Dismantling the Monolith. 2020 , 88, 136-138		13
432	Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease. 2020 , 116, 337-349		8
431	Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. 2020 , 34, 1125-1133		28
430	Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression. 2020 , 120, 104779		6
429	Immune biomarkers alterations in post-traumatic stress disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2020 , 268, 39-46	6.6	28
428	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. 2020 , 45, 990-997		62
427	Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction. 2020 , 185, 311-318		12
426	Antidepressants in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 184-192	24.2	23
425	Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. 2020 , 87, 901-909		129

424	Neuraxial Cytokines in Pain States. 2019 , 10, 3061		37
423	T-cell defects and postpartum depression. 2020 , 87, 397-403		5
422	Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: A randomized placebo-controlled clinical trial. <i>Journal of Affective Disorders</i> , 2020 , 265, 247-254	6.6	21
421	Inflammation affects social experience: implications for mental health. 2020 , 19, 109-110		16
420	Management of Treatment-Resistant Depression: Challenges and Strategies. 2020 , 16, 221-234		70
419	CD3 T cells are critical for the resolution of comorbid inflammatory pain and depression-like behavior. 2020 , 7, 100043		12
418	Molecular adaptations of the blood-brain barrier promote stress resilience vs. depression. 2020 , 117, 3326-3336		86
417	Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. 2020 , 88, 369-380		76
416	Cognitive Deficits in Major Depression: From Mechanisms to Management. 2020 , 51-62		1
415	TNF- α and its soluble receptors mediate the relationship between prior severe mood episodes and cognitive dysfunction in euthymic bipolar disorder. 2020 , 88, 403-410		5
414	Maximising the potential of neuroimmunology. 2020 , 87, 189-192		3
413	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. <i>Journal of Affective Disorders</i> , 2020 , 272, 1-7	6.6	10
412	Antidepressive properties of microglial stimulation in a mouse model of depression induced by chronic unpredictable stress. 2020 , 101, 109931		17
411	Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls. 2020 , 6, 8		7
410	Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation. 2020 , 7, 287-300		11
409	Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges. 2020 , 2020, 2972968		14
408	Prospective associations between hsCRP and GlycA inflammatory biomarkers and depression: The Brazilian longitudinal study of adult health (ELSA-Brasil). <i>Journal of Affective Disorders</i> , 2020 , 271, 39-48	6.6	5
407	Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia. 2020 , 88, 161-165		23

406	Cardiometabolic risk in young adults with depression and evidence of inflammation: A birth cohort study. 2020 , 116, 104682		5
405	Inflammation, reward circuitry and symptoms of anhedonia and PTSD in trauma-exposed women. 2020 , 15, 1046-1055		22
404	The Role of Inflammation in the Treatment of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020 , 11, 160	5	35
403	Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. 2020 , 9,		14
402	Thymoquinone harbors protection against Concanavalin A-induced behavior deficit in BALB/c mice model. 2021 , 45, e13348		3
401	Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. <i>JAMA Psychiatry</i> , 2021 , 78, 161-170	14.5	58
400	Tolerance-inducing effect and properties of innate immune stimulation on chronic stress-induced behavioral abnormalities in mice. 2021 , 91, 451-471		13
399	Advances in novel molecular targets for antidepressants. 2021 , 104, 110041		4
398	A peripheral inflammatory signature discriminates bipolar from unipolar depression: A machine learning approach. 2021 , 105, 110136		22
397	Longitudinal relationships of cytokines, depression and anhedonia in depressed adolescents. 2021 , 91, 74-80		9
396	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. 2021 , 91, 673-682		0
395	Raw and wine processed Schisandra chinensis attenuate anxiety like behavior via modulating gut microbiota and lipid metabolism pathway. 2021 , 266, 113426		15
394	Depression: Biological markers and treatment. 2021 , 105, 110139		17
393	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. 2021 , 133, 82-92		8
392	Depression, dementia and immune dysregulation. 2021 , 144, 746-760		18
391	Towards precision medicine: What are the stratification hypotheses to identify homogeneous inflammatory subgroups. 2021 , 45, 108-121		1
390	Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder. 2021 , 92, 39-48		14
389	Review: Inflammation and anxiety-based disorders in children and adolescents - a systematic review and meta-analysis. 2021 , 26, 143-156		4

388	How Stress Shapes Neuroimmune Function: Implications for the Neurobiology of Psychiatric Disorders. 2021 , 90, 74-84		8
387	Higher baseline interleukin-1 β and TNF- α hamper antidepressant response in major depressive disorder. 2021 , 42, 35-44		7
386	Inflammation in Bipolar Disorder (BD): Identification of new therapeutic targets. 2021 , 163, 105325		20
385	Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis. 2021 , 107, 110209		10
384	Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. 2021 , 107, 110208		3
383	Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. 2021 , 73, 202-277		28
382	Effects of infliximab on brain neurochemistry of adults with bipolar depression. <i>Journal of Affective Disorders</i> , 2021 , 281, 61-66	6.6	3
381	Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review. 2021 , 24, 279-295		8
380	Neuroimmunology of depression. 2021 , 91, 259-292		1
379	Novel therapeutic drug targets for bipolar disorder. 2021 , 393-404		
378	Psychiatric aspects of spondyloarthritis. 2021 , 58, 716-724		0
377	What can neuroimmunology teach us about the symptoms of long-COVID?. 2021 , 2, iqab004		13
376	Immunomodulation with IL-17 and TNF- α in spondyloarthritis: focus on the eye and the central nervous system. 2021 , 13, 1759720X211025894		1
375	Immunomodulation of Resistant Depression. 2021 , 389-400		
374	Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. 2021 , 46, 939-948		50
373	Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study. 2021 , 133, 73-81		11
372	Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study.		0
371	Aging as a Context for the Role of Inflammation in Depressive Symptoms. <i>Frontiers in Psychiatry</i> , 2020 , 11, 605347	5	2

370	Ex vivo glucocorticoid receptor-mediated IL-10 response predicts the course of depression severity. 2021 , 128, 95-104		2
369	[Prospects for the use of drugs with anti-inflammatory properties for the treatment of depression]. 2021 , 121, 124-131		
368	The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases. 2021 , 10,		5
367	Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial. 2021 , 26, 5161-5170		7
366	Is the Association Between Smoking and Depression Mediated by Inflammation? A Mendelian Randomization Study.		1
365	Updated Review and Meta-Analysis of Probiotics for the Treatment of Clinical Depression: Adjunctive vs. Stand-Alone Treatment. 2021 , 10,		19
364	The Role of Inflammatory Proteins in Anti-Glucocorticoid Therapy for Treatment-Resistant Depression. 2021 , 10,		1
363	Role of Inflammation in Depression and Anxiety: Tests for Disorder Specificity, Linearity and Potential Causality of Association in the UK Biobank.		1
362	Personalized Medicine Using Neuroimmunological Biomarkers in Depressive Disorders. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
361	Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder. 2021 , 13, 181-196		2
360	A systematic, integrative review of the effects of the endocannabinoid system on inflammation and neurogenesis in animal models of affective disorders. 2021 , 93, 353-367		1
359	Peripheral inflammatory biomarkers define biotypes of bipolar depression. 2021 , 26, 3395-3406		4
358	A High Level of Noradrenaline in Serum is Related to Depressive Symptoms in Early Pregnancy. 2021 , 11, 2140002		
357	Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. <i>Frontiers in Psychiatry</i> , 2021 , 12, 536257	5	15
356	Prefrontal dopamine D1 receptor manipulation influences anxiety behavior and induces neuroinflammation within the hippocampus. 2021 , 9, 9		5
355	COVID-19 patient transcriptomic and genomic profiling reveals comorbidity interactions with psychiatric disorders. 2021 , 11, 160		9
354	Cytokines changes associated with electroconvulsive therapy in patients with treatment-resistant depression: a Meta-analysis. 2021 , 297, 113735		3
353	Inhibition of acid sphingomyelinase increases regulatory T cells in humans. 2021 , 3, fcab020		1

352	Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. 2021 , 271, 595-607		9
351	Plasma levels of interleukin-6 and antidepressant response to Paroxetine in Chinese depressive patients. 2021 , 297, 113723		0
350	Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders. 2021 , 271, 1331-1341		2
349	Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. 2021 , 16, e0249409		9
348	Expansion of CD4 T Lymphocytes Expressing Interleukin 17 and Tumor Necrosis Factor in Patients with Major Depressive Disorder. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	11
347	TNF- Increase in a Cohort of Depressive Patients. 2021 , 2021, 8897421		0
346	Anti-TNF-Compounds as a Treatment for Depression. 2021 , 26,		5
345	Highlighting the Role of Universally Available and Innate Immune Cell Counts in Acute Ischemic Stroke: A Scoping Review. 2021 , 13, 4069		0
344	Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities. 2021 , 15, 650785		8
343	Higher Levels of Pro-inflammatory Cytokines Are Associated With Higher Levels of Glutamate in the Anterior Cingulate Cortex in Depressed Adolescents. <i>Frontiers in Psychiatry</i> , 2021 , 12, 642976	5	7
342	Childhood inflammatory markers and risks for psychosis and depression at age 24: Examination of temporality and specificity of association in a population-based prospective birth cohort. 2021 , 230, 69-76		6
341	Mental Comorbidity in Rheumatic Diseases. 2021 , 46, 249-257		
340	Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression. 2021 , 38, 451-467		1
339	Dendritic Cells: Neglected Modulators of Peripheral Immune Responses and Neuroinflammation in Mood Disorders?. 2021 , 10,		2
338	Brain-immune crosstalk in the treatment of major depressive disorder. 2021 , 45, 89-107		19
337	Early Life Stress and the Fate of Kynurenine Pathway Metabolites. 2021 , 15, 636144		4
336	Role of Immunity in Pathogenesis of Psychosis.		
335	Hippocampal Glycerol-3-Phosphate Acyltransferases 4 and BDNF in the Progress of Obesity-Induced Depression. 2021 , 12, 667773		3

334	Interleukin-6 secretion upon acute psychosocial stress as a potential predictor of psychotherapy outcome in posttraumatic stress disorder. 2021 , 128, 1301-1310		3
333	Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics. 2021 , 14,		2
332	Inflammation is associated with future depressive symptoms among older adults. <i>Brain, Behavior, & Immunity - Health</i> , 2021 , 13, 100226	5.1	5
331	The Categorization of Pain in Systemic Lupus Erythematosus. 2021 , 47, 215-228		2
330	The Role of the Effects of Autophagy on NLRP3 Inflammasome in Inflammatory Nervous System Diseases. 2021 , 9, 657478		9
329	Vulnerability to inflammation-related depressive symptoms: Moderation by stress in women with breast cancer. 2021 , 94, 71-78		4
328	Psychiatric comorbidity in immune-mediated inflammatory diseases. 2021 , 20, 298-299		3
327	The Impact of Obesity on Microglial Function: Immune, Metabolic and Endocrine Perspectives. 2021 , 10,		4
326	Telomere Shortening and Psychiatric Disorders: A Systematic Review. 2021 , 10,		4
325	The interaction between autophagy and neuroinflammation in major depressive disorder: From pathophysiology to therapeutic implications. 2021 , 168, 105586		5
324	Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank. 2021 , 178, 522-529		30
323	, Suicidal Behavior, and Intermediate Phenotypes for Suicidal Behavior. <i>Frontiers in Psychiatry</i> , 2021 , 12, 665682	5	7
322	Inflammatory signaling mechanisms in bipolar disorder. 2021 , 28, 45		10
321	C-reactive protein as a potential biomarker in psychiatric practice: Are we there yet?. 2021 , 1-14		1
320	Mechanisms and Treatment of Late-Life Depression. 2021 , 19, 340-354		0
319	Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. 2021 , 73, 1084-1117		6
318	Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies. <i>Frontiers in Psychiatry</i> , 2021 , 12, 702617	5	4
317	P2X7 Receptor as a Potential Target for Major Depressive Disorder. 2021 , 22, 1108-1120		3

316	Inflamed brain: Targeting immune changes and inflammation for treatment of depression. 2021 , 75, 304-311	4
315	Treatment resistance in psychiatry: state of the art and new directions. 2021 ,	9
314	Key considerations in the pharmacological management of treatment-resistant depression. 2021 , 22, 2405-2415	0
313	Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link?. 2021 , 12, 699848	4
312	IL-6, sTNF-R2, and CRP in the context of sleep, circadian preference, and health in adolescents with eveningness chronotype: Cross-sectional and longitudinal treatment effects. 2021 , 129, 105241	3
311	An immunogenomic phenotype predicting behavioral treatment response: Toward precision psychiatry for mothers and children with trauma exposure. 2022 , 99, 350-362	2
310	Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study. 2021 , 95, 256-268	12
309	Influences of dopaminergic system dysfunction on late-life depression. 2021 ,	3
308	Mood disorder and cancer onset: evidence from a population-based sample of Australian women. 2021 , 43, 355-361	
307	Pathophysiology of Major Depression by Clinical Stages. 2021 , 12, 641779	1
306	Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link?. 2021 ,	2
305	Gut Microbiota-Derived Inflammation-Related Serum Metabolites as Potential Biomarkers for Major Depressive Disorder. 2021 , 14, 3755-3766	3
304	Metabolomic and Inflammatory Signatures of Symptom Dimensions in Major Depression.	1
303	Influence of dietary habits on depression among patients with rheumatoid arthritis: A cross-sectional study using KURAMA cohort database. 2021 , 16, e0255526	0
302	Adrenergic Attenuation of Immune Activity is Associated with Anhedonia in Adolescents.	
301	Role of inflammation in depression and anxiety: Tests for disorder specificity, linearity and potential causality of association in the UK Biobank. 2021 , 38, 100992	7
300	The Immune System and Anxiety Disorders. 2021 , 233-257	
299	Secondary Mania induced by TNF- β inhibitors: A systematic review. 2021 ,	1

298	Immunotherapies for Depression. 2021 , 139-163		
297	Inflammation, Sickness Behaviour and Depression. 2021 , 109-138		
296	Biomarkers in Child and Adolescent Depression. 2021 , 1		1
295	Different Sides of Depression in the Elderly: An In-depth View on the Role of A β Peptides. 2021 ,		2
294	HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation. <i>Brain Sciences</i> , 2021 , 11,	3-4	9
293	Effectiveness of Immunotherapies for Psychotic Disorders. 2021 , 96-108		
292	Effective Antidepressant Chronotherapeutics (Sleep Deprivation and Light Therapy) Normalize the IL-1 β /IL-1ra Ratio in Bipolar Depression. 2021 , 12, 740686		1
291	Frailty Worsens Antidepressant Treatment Outcomes in Late Life Depression. 2021 , 29, 944-955		2
290	Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline-Results From a Randomized Controlled Clinical Trial. <i>Frontiers in Psychiatry</i> , 2021 , 12, 615261	5	1
289	Lower pro- to anti-inflammatory ratios associated with reduced neurocognitive flexibility in symptomatic adolescents with bipolar disorder. <i>Journal of Affective Disorders</i> , 2021 , 292, 430-438	6.6	2
288	Depression and the Adaptive Immune System. 2021 , 292-308		
287	Transcriptomic signatures of psychomotor slowing in peripheral blood of depressed patients: evidence for immunometabolic reprogramming. 2021 ,		4
286	Rheumatoid arthritis and depression. 2021 , 88, 105200		4
285	Prolonged saturated, but not monounsaturated, high-fat feeding provokes anxiodepressive-like behaviors in female mice despite similar metabolic consequences. <i>Brain, Behavior, & Immunity - Health</i> , 2021 , 16, 100324	5.1	2
284	The impact of stress on immune systems and its relevance to mental illness. 2021 ,		2
283	Building a replicable and clinically-impactful immunopsychiatry: Methods, phenotyping, and theory integration. <i>Brain, Behavior, & Immunity - Health</i> , 2021 , 16, 100288	5.1	4
282	Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression. <i>Brain, Behavior, & Immunity - Health</i> , 2021 , 16, 100313	5.1	1
281	Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study. 2021 , 97, 176-185		10

280	Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders. <i>Brain, Behavior, & Immunity - Health</i> , 2021 , 17, 100335	5.1	2
279	Clinical phenotypes of depressed patients with evidence of inflammation and somatic symptoms. 2021 , 8, 100079		1
278	Dysconnectivity of a brain functional network was associated with blood inflammatory markers in depression. 2021 , 98, 299-309		5
277	Linking childhood trauma and cytokine levels in depressed adolescents. 2021 , 133, 105398		1
276	Psychoneuroimmunology in the context of perinatal depression - Tools for improved clinical practice. <i>Brain, Behavior, & Immunity - Health</i> , 2021 , 17, 100332	5.1	1
275	No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. 2021 , 53, 34-46		4
274	Microglia and BDNF at the crossroads of stressor related disorders: Towards a unique trophic phenotype. 2021 , 131, 135-163		3
273	The emerging tale of microglia in psychiatric disorders. 2021 , 131, 1-29		14
272	Targeting neurotransmitter-mediated inflammatory mechanisms of psychiatric drugs to mitigate the double burden of multimorbidity and polypharmacy. <i>Brain, Behavior, & Immunity - Health</i> , 2021 , 18, 100353	5.1	1
271	Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study. <i>Journal of Affective Disorders</i> , 2021 , 295, 1066-1071	6.6	0
270	Multifaceted interconnections between macrophage migration inhibitory factor and psychiatric disorders. 2022 , 112, 110422		0
269	Antidepressant Drugs: Mechanisms of Action and Side Effects. 2022 , 613-626		
268	Cytokine Effects on Neuronal Processes and on Behavior. 2022 , 728-731		
267	Gut microbiota in mental health and depression: role of pre/pro/synbiotics in their modulation. 2021 , 12, 4284-4314		5
266	Inflammation and Immunity in Schizophrenia. 2021 , 227-240		0
265	Potential biomarkers: differentially expressed proteins of the extrinsic coagulation pathway in plasma samples from patients with depression. 2021 , 12, 6318-6331		3
264	The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. 2021 , 11, 58		12
263	Symptoms: Fatigue and Cognitive Dysfunction. 2015 , 862, 53-75		21

262	Introduction. 2019 , 1180, 1-17	3
261	Biomarker-Guided Tailored Therapy. 2019 , 1192, 199-224	9
260	Role of Inflammation in Psychiatric Disorders. 2019 , 1192, 491-501	4
259	Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. 2020 , 88, 631-639	20
258	Inflammation at the interface of physical and neuropsychiatric outcomes: Investigation of neuroendocrine regulatory pathways to inform therapeutics. 2020 , 88, 270-274	3
257	Depression-free after Interferon- β exposure indicates less incidence of depressive disorder: A longitudinal study in Taiwan. 2020 , 88, 125-131	6
256	Differential effect of interferon-alpha treatment on AEA and 2-AG levels. 2020 , 90, 248-258	4
255	Challenges in researching the immune pathways between early life adversity and psychopathology. 2020 , 32, 1597-1624	5
254	The cortisol:C-reactive protein ratio and negative affect reactivity in depressed adults. 2017 , 36, 852-862	12
253	Depression in Poststroke Aphasia. 2020 , 29, 1798-1810	9
252	Treatment-resistant depression and peripheral C-reactive protein.	1
251	Atypical depression shares genetic predisposition with immuno-metabolic traits: a population-based study.	2
250	Peripheral blood cell immunophenotyping reveals distinct subgroups of inflamed depression.	0
249	Anxiety and depressive symptoms are associated with poor sleep health during a period of COVID-19-induced nationwide lockdown: a cross-sectional analysis of adults in Jordan. 2020 , 10, e041995	17
248	Protocol for the Optimune trial: a randomized controlled trial evaluating a novel Internet intervention for breast cancer survivors. 2020 , 21, 117	3
247	C-reactive protein and clinical subtypes of major depressive disorder at Zagazig University Hospitals. 2020 , 27,	3
246	The role of neuroinflammation on pathogenesis of affective disorders. 2020 , 16, 2-9	25
245	The association between depressive symptoms and insulin resistance, inflammation and adiposity in men and women. 2017 , 12, e0187448	28

244	Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders. 2019 , 57, 318-327	7
243	Ketamine exerts a protective role in a cell-based model of major depressive disorder via the inhibition of apoptosis and inflammation and activation of the Krebs cycle. 2020 , 20, 44-55	4
242	The Inflammatory Hypothesis of Depression: Implications for Diagnosis and Practice. 2016 , 38, 124-138	4
241	Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder. 2015 , 13, 656-62	9
240	Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment. 2016 , 14, 674-87	36
239	Therapeutic Strategies for Treatment of Inflammation-related Depression. 2018 , 16, 176-209	56
238	Imaging the Role of Inflammation in Mood and Anxiety-related Disorders. 2018 , 16, 533-558	135
237	Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. 2014 , 16, 11-27	160
236	Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. 2014 , 16, 539-44	35
235	Pharmacological approaches to the challenge of treatment-resistant depression. 2015 , 17, 111-26	95
234	In immune defense: redefining the role of the immune system in chronic disease. 2017 , 19, 19-26	11
233	Immunological aspects of the treatment of depression and schizophrenia. 2017 , 19, 55-63	40
232	Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders. 2017 , 19, 27-36	7
231	A multispecies approach for understanding neuroimmune mechanisms of stress. 2017 , 19, 37-53	25
230	The Impact of Immunological Factors on Depression Treatment - Relation Between Antidepressants and Immunomodulation Agents. 2019 , 7, 3064-3069	7
229	Assessment and Management of Late-Life Depression. 2014 , 44, 131-137	2
228	Are Mood and Anxiety Disorders Inflammatory Diseases?. 2015 , 45, 240-248	5
227	Anti-Inflammatory Agents as Antidepressants: Truth or Dare. 2015 , 45, 255-261	3

226	More on antidepressant drugs and infectious disease. 2013 , 51, 11-3	4
225	Fat distribution and major depressive disorder in late adolescence. 2016 , 77, 84-9	11
224	Inflammation and Improvement of Depression Following Electroconvulsive Therapy in Treatment-Resistant Depression. 2018 , 79,	38
223	Neuroinflammation and comorbidities are frequently ignored factors in CNS pathology. 2015 , 10, 1349-55	75
222	Depression following a traumatic brain injury: uncovering cytokine dysregulation as a pathogenic mechanism. 2018 , 13, 1693-1704	33
221	Immunoinflammatory Therapies in Psychiatry: Current Evidence Base. 2017 , 39, 721-726	2
220	Immunological changes in depression. 2017 , 26, 201-206	7
219	Poor CD4 count is a predictor of untreated depression in human immunodeficiency virus-positive African-Americans. 2016 , 6, 128-35	12
218	Antidepressant-like Effects Induced by Chronic Blockade of the Purinergic 2X7 Receptor through Inhibition of Non-like Receptor Protein 1 Inflammasome in Chronic Unpredictable Mild Stress Model of Depression in Rats. 2019 , 17, 261-272	16
217	How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. 2020 , 18, 484-492	11
216	Back to the future of psychoneuroimmunology: Studying inflammation-induced sickness behavior. <i>Brain, Behavior, & Immunity - Health</i> , 2021 , 18, 100379	5.1 3
215	Rethinking stress resilience. 2021 , 44, 936-945	4
214	Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effects of electroconvulsive stimulation. 2021 ,	3
213	Increased inflammation predicts nine-year change in major depressive disorder diagnostic status. 2021 , 130, 829-840	4
212	C-Reactive Protein Levels and Gadolinium-Enhancing Lesions Are Associated With the Degree of Depressive Symptoms in Newly Diagnosed Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021 , 12, 719088	4.1
211	Depression in type 2 diabetes: A systematic review and meta-analysis of blood inflammatory markers. 2021 , 134, 105448	4
210	TRPV4 inhibitor HC067047 produces antidepressant-like effect in LPS-induced depression mouse model. 2021 , 201, 108834	1
209	Targeting (Gut)-Immune-Brain Axis with Pharmaceutical and Nutritional Concepts: Relevance for Mental and Neurological Disorders. 2014 , 439-456	

- 208 Cytokines and Related Metabolic Markers in Adult Neuropsychiatric Disorders: Possible Roles in Clinical Application. **2015**, 201-227
- 207 Hippocampal Volumes in PTSD. **2015**, 1-10
- 206 Potential Novel Treatments in Bipolar Depression. **2016**, 259-285
- 205 Role of methylphenidate in the treatment of fatigue in advanced pancreatic cancer population. **2016**, 29, 536-543 3
- 204 Complementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression. **2016**, 67-92
- 203 Hippocampal Volumes in PTSD. **2016**, 1147-1157
- 202 Stress, Cytokines and Depressive Illness?. **2017**,
- 201 Des techniques de neurostimulation [Immuno-psychiatrie]. **2017**, 201, 833-844
- 200 Teaching Neurobiology in Psychiatry. **2018**, 1-27
- 199 Biological Embedding of Child Maltreatment Through Inflammation. **2018**, 1-14 1
- 198 Rheumatoid Arthritis Drugs for Schizophrenia?. **2018**, 48, 232-236
- 197 Novel treatment possibilities in depression and schizophrenia. **2018**, 19, 53-56 1
- 196 The cross-talk between peripheral and central inflammation in depression and the potential for anti-inflammatory treatments. **2018**, 60-71
- 195 Immunopsychiatrie existe-t-elle ?. **2018**, 16, 347-352
- 194 [Anhedonia in the structure of affective disorders: therapeutic opportunities]. **2019**, 119, 116-122 1
- 193 Antidepressants. **2019**,
- 192 Antidepressants. **2019**,
- 191 Depression, GABA and age correlate with the plasma levels of inflammatory markers. 0

- 190 Bipolar Disorder. **2020**, 1-17
- 189 Mapping Immune System Dysfunction to Provide Clinically Actionable Biomarkers and to Understand Psychiatric Pathology. **2020**, 50, 244-249 1
- 188 ARE THEY ALSO MIND COLONIZERS? EXPLORING THE ASSOCIATION BETWEEN GUT MICROBIOTA AND DEPRESSION. **2020**, 4, 168-177
- 187 DNA methylation signatures of C-reactive protein associations with structural neuroimaging measures and major depressive disorder.
- 186 Inflammatory Response and Treatment-Resistant Mental Disorders: Should Immunotherapy Be Added to Pharmacotherapy?. **2020**, 58, 11-16
- 185 Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology. **2020**, 1-40
- 184 Neurological Disorders and Risk of Arrhythmia. **2020**, 22, 8
- 183 Treatment of Childhood Trauma: Pharmacological Approach. **2020**, 431-442
- 182 Unipolar depression. **2020**, 613-631
- 181 Applications of Salivary Bioscience to Precision Medicine. **2020**, 711-721 1
- 180 Bipolar Disorder. **2020**, 297-313
- 179 Burden of depression and anxiety among patients with inflammatory bowel disease: results of a nationwide analysis. **2021**, 1 1
- 178 Inflammatory reactivity to the influenza vaccine is associated with changes in automatic social behavior. **2022**, 99, 339-349 1
- 177 Association between Relative Handgrip Strength and C-Reactive Protein in Adults. **2020**, 38, 164-170
- 176 Depression as an Immunometabolic Disorder: Exploring Shared Pharmacotherapeutics with Cardiovascular Disease. **2020**, 18, 1138-1153 3
- 175 Do cytokines really sing the blues?. **2013**, 2013, 10 13
- 174 Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. **2015**, 12, 26S-40S 13
- 173 The Black Book of Psychotropic Dosing and Monitoring. **2018**, 48, 64-153 1

172	Major Depressive Disorder Following Dermatomyositis: A Case Linking Depression with Inflammation. 2018 , 48, 22-28	2
171	Neuroimaging Advances for Depression. 2017 , 2017,	0
170	Omega-3 fatty acids for depression in adults. 2021 , 11, CD004692	4
169	Novel experimental and early investigational drugs for the treatment of bipolar disorder. 2021 , 1-7	1
168	Novel drug developmental strategies for treatment-resistant depression. 2021 ,	3
167	Neurocircuitry basis of the opioid use disorder-post-traumatic stress disorder comorbid state: conceptual analyses using a dimensional framework. 2021 ,	2
166	Common Fundamentals of Psoriasis and Depression. 2021 , 101, adv00609	0
165	Effects of Subtypes of Child Maltreatment on CRP in Adulthood. <i>Frontiers in Psychiatry</i> , 2021 , 12, 533722;	0
164	Frailty and Depression in Late Life: A High-Risk Comorbidity with Distinctive Clinical Presentation and Poor Antidepressant Response. 2021 ,	2
163	Role of Inflammation in Traumatic Brain Injury-Associated Risk for Neuropsychiatric Disorders: State of the Evidence and Where Do We Go From Here.. 2021 ,	5
162	Increased Inflammation in Depression: A Little in All, or a Lot in a Few?. 2021 , 178, 1077-1079	1
161	Neuropsychiatric disorders: An immunological perspective. 2021 , 152, 83-155	1
160	Prenatal and Childhood Immuno-Metabolic Risk Factors for Adult Depression and Psychosis.. 2022 , 30, 8-23	1
159	Inflammatory Subtypes in Antipsychotic-Naïve First-Episode Schizophrenia are Associated with Altered Brain Morphology and Topological Organization. 2021 , 100, 297-297	3
158	Inflammatory cytokines and callosal white matter microstructure in adolescents.. 2021 , 100, 321-331	0
157	That Gut Feeling: The Role of Inflammatory Cytokines in Depression Among Patients with Inflammatory Bowel Disease. 81-90	0
156	[Microbiota and autoimmune processes as potential therapeutic targets in comorbid depression and inflammatory bowel disease].. 2021 , 121, 134-138	
155	C-Reactive Protein as a Biomarker for Major Depressive Disorder?. 2022 , 23,	1

154	Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?. 2022 , 12, 77-97	3
153	The Brain-Skin Axis in Psoriasis-Psychological, Psychiatric, Hormonal, and Dermatological Aspects.. 2022 , 23,	3
152	Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression.. 2022 , 12, 12	1
151	Immune targets for therapeutic development in depression: towards precision medicine.. 2022 ,	5
150	Brick by Brick: Building a Transdiagnostic Understanding of Inflammation in Psychiatry.. 2022 , 30, 40-53	2
149	Therapeutic effect of Thymoquinone on behavioural response to UCMS and neuroinflammation in hippocampus and amygdala in BALB/c mice model.. 2022 , 239, 47-58	0
148	Precision medicine to manage chronic immune-related conditions. 2022 , 295-318	0
147	Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications.. 2022 , 1	3
146	Stress-induced depressive-like behavior in male rats is associated with microglial activation and inflammation dysregulation in the hippocampus in adulthood. 2022 , 99, 397-408	3
145	The Effects of Peripheral Inflammation on the Brain-A Neuroimaging Perspective.. 2022 , 30, 54-58	4
144	Physical activity as an adjuvant therapy for depression and influence on peripheral inflammatory markers: A randomized clinical trial. 2022 , 22, 100442	1
143	Depression in psoriatic arthritis: Related to socio-demographics, comorbid loads or disease activity?. 2022 ,	
142	Metabolomic and inflammatory signatures of symptom dimensions in major depression.. 2022 , 102, 42-52	1
141	Roles of C-reactive protein polymorphisms and life event changes on cognitive function in bipolar patients receiving valproate.. 2022 , 36, 3946320221084835	0
140	Early Optimized Pharmacological Treatment in Patients With Depression and Chronic Pain.. 2022 , 1-40	
139	Impact of parasitic infection on mental health and illness in humans in Africa: a systematic review.. 2022 , 1-16	0
138	Antidepressant psychopharmacology: is inflammation a future target?. 2022 , 37, 79-81	1
137	A possible causal involvement of neuroinflammatory, purinergic P2X7 receptors in psychiatric disorders.. 2022 ,	0

136	Time for united action on depression: a Lancet-World Psychiatric Association Commission.. 2022 , 399, 957-1022	23
135	No increase in inflammation in late-life major depression screened to exclude physical illness.. 2022 , 12, 118	0
134	Diabetes, antidiabetic medications and risk of depression - A population-based cohort and nested case-control study.. 2022 , 140, 105715	2
133	The role of alcohol use and adiposity in serum levels of IL-1RA in depressed patients.. 2022 , 22, 158	1
132	C-Reactive protein concentrations in reproductive-aged women with major mood disorders.. 2022 , 1	
131	Short-Term Salicylate Treatment Improves Microvascular Endothelium-Dependent Dilation in Young Adults with Major Depressive Disorder.. 2022 ,	
130	Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia.. 2022 ,	0
129	Transcutaneous auricular vagal nerve stimulation inhibits limbic-regional P2X7R expression and reverses depressive-like behaviors in Zucker diabetic fatty rats.. 2022 , 775, 136562	0
128	Treatment-Resistant Depression with Anhedonia: Integrating Clinical and Preclinical Approaches to Investigate Distinct Phenotypes.. 2022 , 104578	0
127	Transcriptomic and cellular decoding of functional brain connectivity changes reveal regional brain vulnerability to pro- and anti-inflammatory therapies.. 2022 ,	0
126	Depression in breast cancer patients: Immunopathogenesis and immunotherapy.. 2022 , 536, 215648	1
125	Increased carotid intima-media thickness is independently associated with the occurrence of depressive disorders in patients with obstructive sleep apnea without cardiocerebrovascular disease.. 2022 , 150, 122-129	
124	Clinical Implications of Cancer Related Inflammation and Depression: A Critical Review.. 2021 , 17, 287-294	0
123	Update on Statin Treatment in Patients with Neuropsychiatric Disorders.. 2021 , 11,	2
122	Inflammaging in Major Depressive Disorder: Associations between markers of inflammation and brain ageing in depression across two large community-based cohorts.	
121	A new experimental design to study inflammation-related versus non-inflammation-related depression in mice.. <i>Journal of Neuroinflammation</i> , 2021 , 18, 290	10.1 1
120	The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study. 2021 , 35, 1479-1487	2
119	m6A Regulator-Mediated RNA Methylation Modification Patterns are Involved in the Pathogenesis and Immune Microenvironment of Depression.. 2022 , 13, 865695	0

118	Cancer-related inflammation and depressive symptoms: Systematic review and meta-analysis.. 2022		1
117	Polyarthrite rhumatoïde et dépression. 2022 ,		
116	Bidirectional association between inflammatory bowel disease and depression among patients and their unaffected siblings.. 2022 ,		0
115	Cerebrospinal Fluid Biomarkers in Patients With Unipolar Depression Compared With Healthy Control Individuals: A Systematic Review and Meta-analysis.. <i>JAMA Psychiatry</i> , 2022 ,	14.5	4
114	Data_Sheet_1.pdf. 2019 ,		
113	Table_1.doc. 2018 ,		
112	DataSheet_1.xlsx. 2020 ,		
111	Table_1.docx. 2020 ,		
110	Table_2.docx. 2020 ,		
109	Relationship between a Self-Reported History of Depression and Persistent Elevation in C-Reactive Protein after Myocardial Infarction.. 2022 , 11,		
108	Younger women are more susceptible to inflammation: A longitudinal examination of the role of aging in inflammation and depressive symptoms.. <i>Journal of Affective Disorders</i> , 2022 , 310, 328-336	6.6	
107	Inflammatory markers and risk factors of RA patients with depression and application of different scales in judging depression.. 2022 , 1		0
106	Childhood trauma, interleukin-17, C-reactive protein, metabolism, and psychosocial functioning in bipolar depression. 2022 , 100357		0
105	Longitudinal assessment of inflammatory markers in the peripartum period by depressive symptom trajectory groups.. <i>Brain, Behavior, & Immunity - Health</i> , 2022 , 22, 100468	5.1	0
104	Long non-coding RNA Tug1 regulates inflammation in microglia and in status epilepticus rats through the NF- κ B signaling pathway. 2022 , 4,		
103	Immunoinflammatory processes: Overlapping mechanisms between obesity and eating disorders?. 2022 , 138, 104688		1
102	Inflammatory stress responses and future mental health outcomes in people with type 2 diabetes. <i>Brain, Behavior, & Immunity - Health</i> , 2022 , 100472	5.1	0
101	Resolution of inflammation: Intervention strategies and future applications. 2022 , 116089		0

100	The modulatory effects of alkaloid extracts of <i>Cannabis sativa</i> , <i>Datura stramonium</i> , <i>Nicotiana tabacum</i> and male <i>Carica papaya</i> on neurotransmitter, neurotrophic and neuroinflammatory systems linked to anxiety and depression.		2
99	Cellular and immunometabolic mechanisms of inflammation in depression: Preliminary findings from single cell RNA sequencing and a tribute to Bruce McEwen. 2022 , 19, 100462		0
98	Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents. 13,		1
97	Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 13,	5	2
96	Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> ,	24.2	2
95	The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation. <i>Brain, Behavior, & Immunity - Health</i> , 2022 , 23, 100480	5.1	
94	A tale of two transmitters: serotonin and histamine as in vivo biomarkers of chronic stress in mice. <i>Journal of Neuroinflammation</i> , 2022 , 19,	10.1	1
93	Association between Peripheral Inflammatory Cytokines and Cognitive Function in Patients with First-Episode Schizophrenia. <i>Journal of Personalized Medicine</i> , 2022 , 12, 1137	3.6	0
92	Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response. <i>Brain Sciences</i> , 2022 , 12, 940	3.4	0
91	Repurposing Anti-inflammatory Agents for Mood Disorders: an Updated Review of Current Evidence. <i>Current Treatment Options in Psychiatry</i> ,	3.1	0
90	Association of Serum Interleukin-8 and Serum Amyloid A With Anxiety Symptoms in Patients With Cerebral Small Vessel Disease. <i>Frontiers in Neurology</i> , 13,	4.1	1
89	Rationale, design, and methods: A randomized placebo-controlled trial of an immunomodulatory probiotic intervention for Veterans with PTSD. <i>Contemporary Clinical Trials Communications</i> , 2022 , 28, 100960	1.8	0
88	Hormone contraceptive use in young women: Altered mood states, neuroendocrine and inflammatory biomarkers. <i>Hormones and Behavior</i> , 2022 , 144, 105229	3.7	
87	The effect of adjunctive infliximab treatment on future cardiovascular disease risk in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2022 ,	6.6	0
86	Interleukin-8 and depressive responses to an inflammatory challenge: secondary analysis of a randomized controlled trial. <i>Scientific Reports</i> , 2022 , 12,	4.9	0
85	Effectiveness of psychocorrective interventions in cardiovascular risk management. 2022 , 28, 235-242		
84	Future of Digital Assays to Resolve Clinical Heterogeneity of Single Extracellular Vesicles. 2022 , 16, 11619-11645		
83	Genetic variants of interleukin 1B and 6 are associated with clinical outcome of surgically treated lumbar degenerative disc disease. 2022 , 23,		

82	ERK1/2-dependent BDNF synthesis and signaling is required for the antidepressant effect of microglia stimulation. 2022 ,	1
81	Pharmacological Strategies for Suicide Prevention Based on the Social Pain Model: A Scoping Review. 2022 , 4, 494-515	
80	Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study.	0
79	The role of the immune system in posttraumatic stress disorder. 2022 , 12,	3
78	Clenbuterol attenuates immune reaction to lipopolysaccharide and its relationship to anhedonia in adolescents. 2022 , 106, 89-99	0
77	Cognitive impairment, childhood trauma, sedentary behaviour, and elevated C-reactive protein levels in major affective disorders. 2022 , 155, 1-9	
76	Severe psychiatric disorders and general medical comorbidities: inflammation-related mechanisms and therapeutic opportunities. 2022 , 136, 1257-1280	0
75	Physical inactivity amplifies the negative association between sleep quality and depressive symptoms. 2022 , 164, 107233	0
74	Epicatechin exerts positive effects on anxiety in high fat diet-induced obese mice through multi-genomic modifications in the hippocampus.	1
73	Effects of Dexamethasone and Pentoxifylline on Mania-like and Depression-like Behaviors in Rats. 2022 , 15, 1063	0
72	Why do we not reverse the path? Stress can cause depression, reduction of brain-derived neurotrophic factor and increased inflammation. 2022 , 12, 1264-1267	0
71	Evidence for Anti-inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial. 2022 , 45, 128-134	0
70	Applying Mendelian randomization to appraise causality in relationships between smoking, depression and inflammation. 2022 , 12,	0
69	Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression. 2022 , 5, e2230367	2
68	Correlation of stress and depression with cancer initiation and progression; a mechanistic review. 2022 , 23,	0
67	Transdiagnostic inflammatory subgroups among psychiatric disorders and their relevance to role functioning: a nested case-control study of the ALSPAC cohort. 2022 , 12,	0
66	Mapping the structure of depression biomarker research: A bibliometric analysis. 13,	0
65	Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions. 2022 ,	0

64	The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?.	0
63	Anti-inflammatory medications for the treatment of mental disorders: A scoping review. 2022 , 26, 100518	1
62	Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression. 2022 , 12, 1403	0
61	Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: a preliminary study. 1-12	0
60	A longitudinal study of the association between pro-inflammatory cytokines and mood symptoms in bipolar disorder.	0
59	Targeting inflammation: a potential approach for the treatment of depression.	1
58	Comparison of serum cytokines levels in normal-weight and overweight patients with first-episode drug-naïve major depressive disorder. 13,	0
57	Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers.	0
56	Inflammatory pathophysiological mechanisms implicated in postpartum depression. 13,	0
55	Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology. 2022 , 25-63	0
54	Inflammation-related functional and structural dysconnectivity as a pathway to psychopathology. 2022 ,	1
53	Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial. 2022 , 26, 100551	0
52	The Role of Inflammation in the Pathophysiology of Depression and Suicidal Behavior. 2023 , 107, 1-29	0
51	Towards a multidimensional model of inflamed depression. 2022 , 100564	0
50	Are serum hsCRP and IL-6 prognostic markers in somatic symptom disorder and related disorders? An exploratory analysis in a prospective cohort study. 2023 , 157, 88-95	0
49	The Tale of Depression and Inflammation Unraveled: On Depression Measurement Levels and Next Steps. 2023 , 93, 211-212	0
48	Exploring the Mechanism of Action of Trachelospermi Caulis et Folium for Depression Based on Experiments: Combining Network Pharmacology and Molecular Docking. 2022 , 2022, 1-17	0
47	Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies.	0

- 46 How does IL-6 change after combined treatment in MDD patients? A systematic review. **2022**, 100579 ○
- 45 Once induced, it lasts for a long time: the structural and molecular signatures associated with depressive-like behavior after neonatal immune activation. 16, ○
- 44 Corticostriatal contributions to dysregulated motivated behaviors in stress, depression, and substance use disorders. **2022**, ○
- 43 Depression in Women With Inflammatory Bowel Disease: A Multifaceted Approach for a Multidimensional Problem. ○
- 42 Neuroinflammation in the amygdala is associated with recent depressive symptoms. ○
- 41 Dopamine, Immunity and Disease. PHARMREV-AR-2022-000618 1
- 40 Anxiety, Depression and Quality of Life After Achievement of Inactive/Low Disease Activity in Axial-Spondyloarthritis. ○
- 39 Impact of depression on the quality of sleep and immune functions in patients with coronary artery disease. **2022**, 35, e100918 ○
- 38 Anti-inflammatory properties of commonly used psychiatric drugs. 16, ○
- 37 Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses. Volume 19, 1-25 ○
- 36 Fluoxetine and Curcumin Prevent the Alterations in Locomotor and Exploratory Activities and Social Interaction Elicited by Immunoinflammatory Activation in Zebrafish: Involvement of BDNF and Proinflammatory Cytokines. ○
- 35 Microglia transcriptional profiling in major depressive disorder shows inhibition of cortical grey matter microglia. ○
- 34 Inflammation, stress and depression: an exploration of ketamine's therapeutic profile. **2023**, 103518 ○
- 33 The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders. **2023**, 513-535 ○
- 32 Amphetamines abuse and depression: Focus on TRPC channels. **2023**, 364, 114391 ○
- 31 Not immune to stress: LBP's link to depression. **2023**, 56, 469-471 ○
- 30 Serum claudin-5 levels among patients with unipolar and bipolar depression in relation to the pro-inflammatory cytokine tumor necrosis factor-alpha levels. **2023**, 109, 162-167 ○
- 29 Relationship between antenatal sleep quality and depression in perinatal women: A comprehensive meta-analysis of observational studies. **2023**, 327, 38-45 ○

28	Association of systemic inflammatory biomarkers with depression risk: Results from National Health and Nutrition Examination Survey 2005-2018 analyses. 14,	o
27	Depression Is Associated with an Increased Risk of Subsequent Cancer Diagnosis: A Retrospective Cohort Study with 235,404 Patients. 2023 , 13, 302	o
26	Physical activity as a promising alternative for young people with juvenile idiopathic arthritis: Towards an evidence-based prescription. 14,	o
25	Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective true-to-life study. 2023 , 13, 204512532211354	o
24	Biological subtyping of psychiatric syndromes as a pathway for advances in drug discovery and personalized medicine. 2023 , 1, 88-99	o
23	Targeting Underlying Inflammation in Carcinoma Is Essential for the Resolution of Depressiveness. 2023 , 12, 710	1
22	Cytokines in psychosis: from mechanism towards treatment and prediction. 2023 , 10, 237-239	o
21	Lipopolysaccharide-binding protein expression is increased by stress and inhibits monoamine synthesis to promote depressive symptoms. 2023 , 56, 620-634.e11	o
20	Disrupting the Mood and Obesity Cycle: The Potential Role of Metformin. 2023 , 3, 59-75	o
19	Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. 2023 , 180, 190-199	1
18	Brain Ventricle and Choroid Plexus Morphology as Predictor of Treatment Response: Findings from the EMBARC Study.	o
17	Health-related quality of life and symptoms in autoimmune liver diseases. 2023 , 69,	o
16	Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation. 14,	o
15	Increased Inflammation and Treatment of Depression: From Resistance to Reuse, Repurposing, and Redesign. 2023 , 387-416	o
14	Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics. 2023 , 287-297	o
13	Shared and differential fractional amplitude of low-frequency fluctuation patterns at rest in major depressive disorders with or without sleep disturbance. 14,	o
12	Early Life Stress, Neuroinflammation, and Psychiatric Illness of Adulthood. 2023 , 105-134	o
11	Suicide and Inflammation. 2023 , 379-404	o

- 10 C-Reactive Protein (CRP): A Potent Inflammation Biomarker in Psychiatric Disorders. **2023**, 135-160 ○
- 9 Sleep Duration and Risk of Depression: Empirical Evidence from Chinese Middle-Aged and Older Adults. **2023**, 15, 5664 ○
- 8 Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis. **2023**, 13, e067944 ○
- 7 Elevated C-Reactive Protein Levels Modify the Effect of Magnesium on Depressive Symptoms: A Population-Based Study. **2023**, 15, 1560 ○
- 6 BNIP3L/NIX-mediated mitophagy alleviates passive stress-coping behaviors induced by tumor necrosis factor- β ○
- 5 Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders. **2023**, 180, 259-261 1
- 4 The emerging science of Glioseption: Contribution of glia in sensing, transduction, circuit integration of interoception. **2023**, 245, 108403 ○
- 3 A Role for Blood-brain Barrier Dysfunction in Delirium following Non-Cardiac Surgery in Older adults. ○
- 2 Signatures of HIV and Major Depressive Disorder in the Plasma Microbiome. **2023**, 11, 1022 ○
- 1 Sickness Behaviour and Depression: An Updated Model of Peripheral-Central Immunity Interactions. **2023**, ○